<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurochem Res</journal-id><journal-id journal-id-type="iso-abbrev">Neurochem Res</journal-id><journal-title-group><journal-title>Neurochemical Research</journal-title></journal-title-group><issn pub-type="ppub">0364-3190</issn><issn pub-type="epub">1573-6903</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39751928</article-id><article-id pub-id-type="pmc">PMC11698766</article-id>
<article-id pub-id-type="publisher-id">4302</article-id><article-id pub-id-type="doi">10.1007/s11064-024-04302-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Breaking Barriers in Huntington&#x02019;s Disease Therapy: Focused Ultrasound for Targeted Drug Delivery</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0002-6387-623X</contrib-id><name><surname>Helal</surname><given-names>Mohamed Mohsen</given-names></name><address><email>helal.rsch@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ibrahim</surname><given-names>Arwa Amer</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Beddor</surname><given-names>Ahmad</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5624-0017</contrib-id><name><surname>Kashbour</surname><given-names>Muataz</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/053g6we49</institution-id><institution-id institution-id-type="GRID">grid.31451.32</institution-id><institution-id institution-id-type="ISNI">0000 0001 2158 2757</institution-id><institution>Faculty of Medicine, </institution><institution>Zagazig University, </institution></institution-wrap>Zagazig, Egypt </aff><aff id="Aff2"><label>2</label>Medical Research Group of Egypt, Negida Academy, Arlington, MA USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00engpz63</institution-id><institution-id institution-id-type="GRID">grid.412789.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 4686 5317</institution-id><institution>College of Medicine, </institution><institution>University of Sharjah, </institution></institution-wrap>Sharjah, United Arab Emirates </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/004mbaj56</institution-id><institution-id institution-id-type="GRID">grid.14440.35</institution-id><institution-id institution-id-type="ISNI">0000 0004 0622 5497</institution-id><institution>Faculty of Medicine, </institution><institution>Yarmouk University, </institution></institution-wrap>Irbid, Jordan </aff><aff id="Aff5"><label>5</label>Diagnostic Radiology Department, National Cancer Institute, Misrata, Libya </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>50</volume><issue>1</issue><elocation-id>68</elocation-id><history><date date-type="received"><day>18</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>14</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Huntington&#x02019;s disease (HD) is a progressive neurodegenerative disease resulting from a mutation in the huntingtin (HTT) gene and characterized by progressive motor dysfunction, cognitive decline, and psychiatric disturbances. Currently, no disease-modifying treatments are available. Recent research has developed therapeutic agents that may have the potential to directly target the disease pathology, such as gene silencing or clearing the mutant protein. However, these agents are limited by their inability to cross the blood-brain barrier (BBB), preventing optimal therapeutic effects. Although various techniques have been explored to overcome the BBB, focused ultrasound (FUS) has emerged as a promising non-invasive therapeutic modality offering the potential for targeted intervention in neurodegenerative diseases, including HD. Preclinical studies demonstrated the safety and efficacy of FUS in delivering therapeutic agents, such as siRNAs and AAV vector-based gene therapy, resulting in significant reductions in mutant HTT expression and improvements in motor function in HD mouse models. Furthermore, the safety profile of FUS-induced BBB opening has been established in clinical trials on human patients of neurodegenerative diseases other than HD, showing no adverse effects on brain structure or function. This review provides a comprehensive overview of the current state of FUS research in HD and connects existing evidence from neurodegenerative disease studies with its promise in establishing disease-modifying therapies for HD.</p><sec><title>Graphical Abstract</title><p id="Par2">
<fig position="anchor" id="Figa"><caption><p>Created with BioRender [<xref ref-type="bibr" rid="CR1">1</xref>]</p></caption><graphic position="anchor" xlink:href="11064_2024_4302_Figa_HTML" id="d33e223"/></fig>
</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Huntington's disease</kwd><kwd>Focused ultrasound</kwd><kwd>Neurodegenerative diseases</kwd><kwd>Blood-brian barrier</kwd><kwd>Drug delivery</kwd><kwd>Clinical trials</kwd></kwd-group><funding-group><award-group><funding-source><institution>Zagazig University</institution></funding-source></award-group><open-access><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">Huntington&#x02019;s disease (HD) is a genetic neurodegenerative disorder affecting more than 30,000 people in the US and putting more than 200,000 at risk of its inheritance [<xref ref-type="bibr" rid="CR2">2</xref>]. The culprit genetic mutation is an abnormal expansion of the trinucleotide repeat CAG (cytosine-adenine-guanine) in the huntingtin (HTT) gene (IT-15 previously) found on the short arm (p) of chromosome 4 [<xref ref-type="bibr" rid="CR3">3</xref>]. This mutation results in the production of the HTT protein with an abnormally high number of glutamine amino acids (polyglutamine-expanded aggregates) [<xref ref-type="bibr" rid="CR3">3</xref>]. These cellular-based changes result in the degeneration of neurons, particularly the cerebral cortex and basal ganglia. Therefore, HD leads to a variety of motor, psychological, and cognitive symptoms.</p><p id="Par4">HD typically begins in middle age and progresses over time. The main motor symptom of HD is chorea [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], which is substituted by akinesia with the progression of the disease. In addition, many psychiatric manifestations are documented to accompany HD, like bipolar disorders and obsessive-compulsive disorder, and the most commonly associated one is depression [<xref ref-type="bibr" rid="CR3">3</xref>]. Its devastating psychological effect extends to patients&#x02019; suicidal attempts. A cohort study of HD patients revealed that suicide forms 3&#x02013;7% of HD-related deaths [<xref ref-type="bibr" rid="CR6">6</xref>]. Furthermore, its cognitive symptoms primarily involve deficits in memory, speech, vision, processing, attention, and other cognitive functions [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Moreover, dementia usually develops, making HD patients fully dependent on caregivers for their everyday activities [<xref ref-type="bibr" rid="CR9">9</xref>]. Now, HD dementia is considered a differential diagnosis of dementia with Alzheimer&#x02019;s disease (AD) and Parkinson&#x02019;s disease (PD) dementias and has full criteria to be diagnosed [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par5">HD is transmitted in an autosomal dominant manner and exhibits <italic>complete penetrance</italic>, ensuring that every person with the mutation will develop the disease [<xref ref-type="bibr" rid="CR3">3</xref>]. A key feature of HD is the instability of the CAG trinucleotide repeats within the HTT gene, which tend to expand in size with each generation, leading to a phenomenon known as genetic anticipation. This phenomenon results in an earlier and more severe presentation of HD in subsequent generations, making it increasingly challenging to manage. Addressing this progressive nature of HD necessitates the development of effective treatments to interrupt the disease cycle.</p><p id="Par6">Recent advances in medical research have significantly improved our understanding of the role of the HTT gene mutation in the pathology of the disease. Several theories have been adopted, including mitochondrial dysfunction, proteolysis by caspases and other proteases, and excitotoxicity [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. The first one supposes that the mutant HTT (mHTT) leads to mitochondrial dysfunction as a result of impaired calcium regulation and reduced adenosine triphosphate (ATP) production, which finally causes neuronal cell apoptosis [<xref ref-type="bibr" rid="CR13">13</xref>]. The proteolysis theory suggests that cytotoxicity and neurodegeneration result from the cleavage of HTT protein in the cytoplasm and translocation of the fragments into the nucleus [<xref ref-type="bibr" rid="CR11">11</xref>]. These theories have set the stage for potential therapeutic agents that could compensate for such changes. For instance, creatine and coenzyme Q10 are being explored to address mitochondrial dysfunction as they act as a source of ATP, caspase-6 inhibitors for proteolysis, and riluzole for excitotoxicity [<xref ref-type="bibr" rid="CR13">13</xref>]. Additionally, stem cell therapies are being investigated to address neuronal cell loss.</p><p id="Par7">Nevertheless, given the identified primary pathology underpinning HD, which is the mHTT, various HTT-lowering strategies are being developed. Such strategies focus on disrupting the DNA or RNA of mHTT or preventing the aggregation of the abnormal HTT protein in neuronal cytoplasm. Among these, interfering RNA of the HTT gene is the most advanced strategy for this purpose, having been tested in phase I, II, and III clinical trials [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. RNA interference is implemented through a variety of available methods, including, but not limited to, antisense oligonucleotides (ASOs), which are widely used, single-stranded RNA molecules (ssRNAs), and artificial microRNAs (miRNAs) [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. ASOs exert their silencing action by binding to the HTT mRNA and interrupting the biosynthesis of the protein [<xref ref-type="bibr" rid="CR3">3</xref>]. Other RNA interference strategies have a mechanism of action similar to that of ASOs [<xref ref-type="bibr" rid="CR20">20</xref>]. Additionally, disrupting DNA has been proposed as a potentially effective approach. By directly targeting the mutant gene (and reducing the number of CAG repeats), it could delay disease onset and alleviate symptoms [<xref ref-type="bibr" rid="CR20">20</xref>]. However, this strategy has not yet progressed beyond preclinical studies.</p><p id="Par8">A significant debate surrounding the aforementioned HTT knockdown strategies stems from the recognized physiological functions of the HTT gene and protein in human brain development, neuronal survival, protein synthesis, and impulse transmission [<xref ref-type="bibr" rid="CR21">21</xref>]. However, the complete physiological role of HTT remains unclear. To address this, various preclinical trials investigating the effects of HTT silencing have been conducted, yielding mixed results [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Consequently, the potential negative consequences of implementing such strategies in humans are still uncertain [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par9">Currently, there are no approved disease-modifying treatments for HD [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. The available therapies mainly focus on symptomatic management. Chorea is typically managed with presynaptic dopamine-depleting agents such as tetrabenazine [<xref ref-type="bibr" rid="CR3">3</xref>]. Depression is often treated by selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, and dementia is treated by cholinesterase inhibitors [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par10">One of the primary <italic>challenges</italic> in treating neurodegenerative diseases, such as HD, is the inability to deliver therapeutic agents across the <italic>blood-brain barrier (BBB)</italic>. The BBB serves as a protective layer that shields the brain from harmful substances but also restricts the penetration of many drugs [<xref ref-type="bibr" rid="CR27">27</xref>]. In certain cases, the BBB can significantly impede the delivery of therapeutic agents, preventing them from reaching effective concentrations in the brain [<xref ref-type="bibr" rid="CR28">28</xref>]. This limitation has hindered the clinical application of numerous compounds that have demonstrated efficacy in treating brain diseases during animal studies by direct delivery methods.</p><p id="Par11">For a drug to be suitable for clinical use, it must effectively penetrate BBB while being administered through a <italic>non-invasive</italic> route. This requirement is essential to ensure that therapeutic agents can reach the brain safely and efficiently, minimizing the risks associated with invasive procedures.</p><p id="Par12">In HD research, therapies are continually evolving to address the various theories of disease pathogenesis. For instance, small interfering RNA (siRNA), which is one of RNA interference methods, has shown a favorable safety profile and efficacy in reducing levels of mHTT in non-human primates and mouse models following direct injections into the brain parenchyma or ventricles [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. However, it must be delivered in a less invasive manner and successfully cross the BBB to achieve adequate brain concentrations to be a viable treatment option for humans with HD. Research using various materials and methods is exploring the most effective approach to achieve this goal [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par13">Among the techniques used to overcome the BBB, one promising and emerging strategy is <italic>Focused Ultrasound (FUS)</italic>. FUS has demonstrated its potential as a non-invasive and targeted brain delivery method [<xref ref-type="bibr" rid="CR33">33</xref>]. This is particularly beneficial in neurodegenerative diseases since more localized treatment may be more effective. FUS has enhanced the effectiveness of various HD therapies, such as siRNA, glial cell line-derived neurotrophic factor (GDNF), and adeno-associated virus (AAV) vector-based gene therapies, through effective BBB opening in animal models. This approach could revolutionize the treatment of HD disease. Although FUS-mediated treatments of neurodegenerative diseases are in various stages of basic, preclinical, and clinical research, they offer hope that HD may one day be treatable [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. However, many challenges remain before these therapies become available alternatives. Here, we provide a comprehensive review of FUS-mediated BBB opening in HD. We also highlight the promising potential and future directions for managing HD using FUS.</p></sec><sec id="Sec2"><title>Crossing the BBB: Strategies for Medication Delivery and Associated Challenges</title><p id="Par14">The BBB is a semipermeable, multicellular structure within the brain&#x02019;s capillaries that encloses and protects the brain from harmful substances such as toxins, certain drugs, and microorganisms [<xref ref-type="bibr" rid="CR27">27</xref>]. It plays a crucial role in regulating the brain&#x02019;s microenvironment and maintaining homeostasis [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>]. Due to its highly selective permeability, it represents one of the most resistant barriers in the body [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par15">The primary structural unit of the BBB is the <italic>neurovascular unit (NVU)</italic> [<xref ref-type="bibr" rid="CR27">27</xref>], which consists of specialized endothelial cells (ECs), pericytes, astrocytes, adjacent neurons, and the basement membrane. These components work together to maintain the integrity and function of the BBB. The ECs are interconnected by tight junctions (TJs) and adherens junctions (AJs), which limit paracellular permeability. Unlike peripheral capillaries, the ECs of the BBB lack fenestrations, further restricting transcellular permeability [<xref ref-type="bibr" rid="CR40">40</xref>]. Moreover, these ECs contain significantly fewer vesicles, which limit intracellular transcytosis, and they are equipped with numerous efflux transporters, such as P-glycoprotein, which actively pump drugs out of the brain [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par16">Collectively, the NVU forms an extensive network that encloses approximately 600&#x000a0;km of capillaries within the human brain [<xref ref-type="bibr" rid="CR42">42</xref>]. This extensive barrier creates a significant challenge in the delivery of neurotherapeutic agents, effectively blocking 98% of small-molecule neurological drugs and nearly 100% of larger ones [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par17">Research has been focused on overcoming the BBB&#x02019;s selective permeability and the associated challenges in delivering neurotherapeutics since the late 20th century. Applying hyperosmotic solutions, e.g., mannitol and urea, was commonly used in the first attempts at BBB opening [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. These solutions cause cellular shrinkage, which leads to the loosening of the TJs between ECs, thereby increasing paracellular permeability [<xref ref-type="bibr" rid="CR45">45</xref>]. However, this method requires invasive intra-arterial catheterization and produces off-target openings in the territory of the injected vessel [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par18">To overcome the diffuse effect, researchers tried direct injection of the drugs into the target brain region through the skull [<xref ref-type="bibr" rid="CR47">47</xref>]. Although this approach to overcoming the BBB is more targeted, it is highly invasive and carries significant risks, including infection, bleeding, and tissue damage. To address these limitations, non-invasive techniques such as FUS have emerged, offering a controllable method to temporarily disrupt the BBB for drug delivery without the need for invasive procedures [<xref ref-type="bibr" rid="CR33">33</xref>].</p><sec id="Sec3"><title>Mechanisms and Evolution of FUS for BBB Opening</title><p id="Par19">FUS has undergone significant advancements, demonstrating its effectiveness in non-invasively opening the BBB while overcoming the limitations associated with other techniques [<xref ref-type="bibr" rid="CR48">48</xref>]. One of the key advantages of FUS is its ability to create <italic>localized</italic> openings in the BBB without causing damage to surrounding neurons [<xref ref-type="bibr" rid="CR48">48</xref>]. Notably, a pioneering study revealed that FUS-mediated BBB openings are transient, allowing the barrier to heal and restore its normal function and structure following sonication [<xref ref-type="bibr" rid="CR49">49</xref>]. This unique characteristic of FUS, along with others, not only minimizes potential risks but also underscores its promise in the treatment of chronic brain diseases that necessitate long-term drug administration.</p><p id="Par20">FUS acts through temporarily <italic>disrupting</italic> the internal mechanisms of the BBB and its endothelial cells (ECs). Typically, FUS is combined with the intravascular administration of microbubbles (MBs) [<xref ref-type="bibr" rid="CR40">40</xref>]. MBs, which are gas-filled components of a contrast agent injected prior to FUS application, have physical parameters that significantly affect the resulting BBB disruption [<xref ref-type="bibr" rid="CR50">50</xref>].</p><p id="Par21">Upon sonication of the target region, the MBs undergo rhythmic contraction and expansion, generating shear forces on the blood vessels in this area&#x02014;a phenomenon known as the &#x0201c;cavitation effect&#x0201d; [<xref ref-type="bibr" rid="CR51">51</xref>]. This physical interplay between the ultrasound beam, MBs, and the vessel walls temporarily opens the TJs between the ECs of the BBB, increasing paracellular permeability and facilitating drug delivery for a limited duration (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par22">Further research into the mechanisms by which FUS produces BBB disruption has revealed additional effects of FUS combined with MBs that impact nearly every aspect of ECs functions. Studies have demonstrated that FUS&#x02009;+&#x02009;MB increases the number of intracellular vesicles, thereby promoting transcytosis within BBB ECs [<xref ref-type="bibr" rid="CR52">52</xref>]. Additionally, exposure to FUS&#x02009;+&#x02009;MB is believed to decrease the number of efflux transporters, which limits the removal of therapeutic agents from the brain and enhances their therapeutic effects [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>].</p><p id="Par23">Furthermore, FUS combined with microbubbles offers a wide range of options for modulating its effects on the BBB and surrounding tissue. By calibrating ultrasound parameters such as pulse repetition frequency (PRF), pressure, and burst duration, as well as adjusting MBs characteristics like the type, dose concentration, distribution, and half-life, researchers can tailor the technique according to skull thickness, target depth, and the desired degree of effect [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par24">Numerous preclinical studies have aimed to optimize the parameters of FUS and MBs for maximal safety and efficacy in BBB opening by exploring the effect of changes in each parameter [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. One study applied FUS&#x02009;+&#x02009;MB with varying parameters across 100 different non-overlapping brain regions in rabbits, finding that FUS burst length was the only parameter that significantly altered the extent of BBB disruption, while MBs dose and PRF had no effect [<xref ref-type="bibr" rid="CR51">51</xref>]. In contrast, Shin et al. concluded from their optimization trial on rats that the MBs dose and the PRF could affect the magnitude of BBB disruption [<xref ref-type="bibr" rid="CR54">54</xref>]. Species differences in skull thickness and brain volume can affect acoustic attenuation, potentially limiting the translation of FUS to clinical trials due to a lack of optimization. However, extensive research has established key findings regarding FUS&#x02009;+&#x02009;MB characteristics for human-tolerated schemes; for instance, acoustic pressure and MBs diameter are directly related to the degree of BBB opening [<xref ref-type="bibr" rid="CR40">40</xref>]. The clinical relevance of these findings is substantial. For example, a specific range of acoustic pressure (0.2&#x02013;1.0&#x000a0;MPa) is utilized in clinical trials for FUS-mediated BBB opening [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>].</p><p id="Par25">Moreover, magnetic resonance imaging-guided FUS (MRgFUS) has further enhanced the technique by enabling <italic>real-time monitoring</italic> of the drug delivery process and intraoperative feedback. This is possible through real-time MR thermography and acoustic spectrum monitoring (size and site of the target) [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. In addition, evaluation of the effects of changing certain FUS or MBs parameters was possible using MRI through quantification of the barrier interruption and drug penetration [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR60">60</xref>].</p><p id="Par26">It is important to note that the FUS technology discussed in this review specifically refers to <italic>low-intensity FUS (LIFUS)</italic>, which is applied in BBB opening trials. In contrast, high-intensity FUS (HIFUS) utilizes high-energy ultrasonic waves for thermal ablation of tissues or neuromodulation and is currently approved for the treatment of some tumors, PD, and essential tremors [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>].</p><p id="Par27">Demonstrating these valuable properties and versatility, FUS has transformed the field of BBB opening and, consequently, the treatment of neurodegenerative diseases. Currently, FUS has been under the scope of clinical research for years after showing favorable safety and efficacy profiles in BBB opening in animal models of neurodegenerative diseases. It has been applied in clinical trials of AD, PD, and amyotrophic lateral sclerosis (ALS) and proved its safety for human application (with some trials reporting no adverse events) [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR62">62</xref>&#x02013;<xref ref-type="bibr" rid="CR64">64</xref>]. However, its efficacy as a drug delivery system for neurodegenerative disease patients has not been proven yet. In addition, FUS has not been tested in HD patients before. Therefore, summarizing the existing preclinical evidence regarding its application in HD models will provide insights into its potential as a drug delivery method for HD.</p><p id="Par28">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Schematic Illustration of the Mechanism of FUS-Induced BBB Opening: This figure illustrates how focused ultrasound (FUS) combined with microbubbles (blue) enhances drug delivery across the blood-brain barrier (BBB). In Panel A, FUS is applied externally to the head, causing the injected microbubbles in the bloodstream to oscillate and temporarily disrupt the BBB, allowing drug molecules (gray) to enter the brain. Panel B shows that FUS increases transcytosis across endothelial cells, facilitating drug transport from the blood to the brain. Finally, Panel C demonstrates that FUS can inhibit efflux transporters, which usually pump drugs out of the brain, enabling drugs to stay in the brain longer. Figure created with BioRender [<xref ref-type="bibr" rid="CR1">1</xref>]</p></caption><graphic xlink:href="11064_2024_4302_Fig1_HTML" id="d33e607"/></fig>
</p></sec><sec id="Sec4"><title>FUS in HD: Preclinical Evidence</title><p id="Par29">In recent years, FUS has garnered attention as a promising technique for enhancing treatments for HD by facilitating drug delivery to the brain. This innovative method has significantly increased the bioavailability of neuroprotective agents, improving therapeutic outcomes. Recent preclinical trials in mouse models have demonstrated the safety and efficacy of FUS-mediated delivery systems to enhance therapeutic outcomes by improving motor function and reducing toxic protein aggregates in HD [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>].</p></sec><sec id="Sec5"><title>GDNF</title><p id="Par30">One promising approach to HD treatment involves delivering GDNF to the affected neurons. GDNF is a neurotrophic protein encoded by the GDNF gene. It is naturally expressed in healthy brains, exerts neuroprotective effects, and promotes their survival and maintenance by signaling through GFR&#x003b1;1 receptors [<xref ref-type="bibr" rid="CR67">67</xref>]. GDNF overexpression has been found to have positive neuroprotective effects in HD patients [<xref ref-type="bibr" rid="CR68">68</xref>]. However, delivering GDNF to targeted areas of the brain is challenging because it does not efficiently cross the BBB.</p><p id="Par31">Current methods for GDNF administration, such as intrastriatal or intraventricular injections, are invasive [<xref ref-type="bibr" rid="CR69">69</xref>], which may have adverse effects on the patient&#x02019;s health and may also diminish the potential therapeutic benefits. A previous study assessing the safety of intracerebroventricular catheter implantation for GDNF delivery in PD reported several adverse events, including paraesthesia, nausea, weight loss, and asymptomatic hyponatremia, without significant improvement in symptoms [<xref ref-type="bibr" rid="CR69">69</xref>]. A case report highlighted the adverse effects experienced by a PD patient following GDNF injections, noting a lack of improvement in parkinsonism and a worsening of symptoms, including hallucinations, depression, nausea, and loss of appetite [<xref ref-type="bibr" rid="CR70">70</xref>]. Such findings highlight the need for alternative, less invasive delivery methods.</p><p id="Par32">FUS-induced BBB opening has shown promise as an alternative approach to delivering GDNF. In a study using HD mouse models, FUS was used to deliver GDNF plasmid DNA (GDNFp) into HD mice and reported positive results [<xref ref-type="bibr" rid="CR65">65</xref>]. The animal model used in the study is a transgenic mouse model for HD, specifically the R6/2 HD mice. The R6/2 HD mice exhibit similar symptoms to human HD, including motor impairments and neuropathological features like protein aggregation, oxidative stress, and neuroinflammation. MRI and histological staining demonstrated the efficacy of FUS-induced BBB opening in mice without significant capillary or brain tissue damage. The study showed increased BBB permeability in the sonicated brains of both HD and wild-type (WT) mice and effective extravasation of GDNFp-liposomes (GDNFp-LPs) into the CNS, resulting in an increase in GDNF protein expression in the target cells.</p><p id="Par33">To investigate the pathological changes, multiple immunohistochemical stainings showed significant reductions in HTT protein aggregates in the cortex and striatum of HD mice, indicating a positive therapeutic effect. Additionally, there was a significant increase in the expression of the neuronal survival marker, phosphorylated cAMP response element-binding protein (P-CREB), and improved motor performance in the treated HD mice. Elevated levels of microtubule-associated protein 2 (MAP2) suggested enhanced neurite outgrowth. As a result, neurogenesis was found to be a potential outcome of the GDNF treatment, further supporting the efficacy of this non-invasive FUS-mediated BBB opening technique for gene therapy in addressing the neurodegenerative processes associated with HD.</p><p id="Par34">The promising preliminary findings of this study lead future research to focus on modifying FUS parameters to maximize GDNF delivery, evaluating the long-term outcomes in larger animal models, and transitioning to trials on humans. This method not only improves neuronal survival and neuroprotection but also supports neurogenesis, which is critical for tackling the neurodegenerative aspects of HD. Additionally, gene therapy and genetic engineering integration to utilize more effective delivery methods can pave the way for breakthroughs in HD treatments.</p></sec><sec id="Sec6"><title>Oligonucleotide-Based Therapies</title><p id="Par35">Given that the mHTT protein is the primary cause of HD, oligonucleotide-based therapies using siRNAs and antisense oligonucleotides, designed to specifically silence mHTT, hold promise as novel treatments [<xref ref-type="bibr" rid="CR71">71</xref>]. siRNAs are small, double-stranded RNA molecules that can degrade mRNA, preventing its translation into proteins and thus reducing the production of the mHTT protein [<xref ref-type="bibr" rid="CR72">72</xref>]. However, the BBB poses a significant challenge as it hinders the efficient delivery of siRNA molecules [<xref ref-type="bibr" rid="CR72">72</xref>]. Previous studies, such as Wang et al. [<xref ref-type="bibr" rid="CR73">73</xref>], used invasive delivery methods of siRNAs in HD mice, such as intraventricular injections. FUS may provide a more precise and less invasive solution, enabling targeted delivery to critical brain regions.</p><p id="Par36">A key investigation in this area was conducted by Burgess et al. [<xref ref-type="bibr" rid="CR32">32</xref>], who demonstrated the efficacy of FUS in delivering siRNA to knock down mHTT gene expression in HD adult Wistar rats models. MRI confirmed the effective temporary disruption of the BBB, enabling cholesterol-conjugated siRNA that targets the HTT gene (cc-siRNA-HTT) to penetrate the targeted brain areas. Post-treatment analysis showed a significant, dose-dependent reduction in HTT mRNA levels in the striatum, with the optimal dose and maximum reduction observed being approximately 32%. Furthermore, a direct correlation was found between the extent of BBB disruption and the degree of HTT mRNA reduction, emphasizing the significance of precise control over the FUS parameters. This targeted delivery system showed specificity for the mHTT mRNA without significant off-target effects, enhancing safety and reducing the risk of systemic side effects.</p><p id="Par37">Similar innovative approaches are being explored with adeno-associated virus (AAV) vectors to further enhance gene therapy for HD. AAV is particularly beneficial because it can deliver genetic material to both dividing and non-dividing cells and has a low immunogenicity profile, making it suitable for long-term gene expression. In HD, researchers are investigating AAV9 to deliver therapeutic genes aimed at mitigating the effects of the disease, which is characterized by progressive neurodegeneration [<xref ref-type="bibr" rid="CR74">74</xref>]. However, delivering AAV across the BBB remains challenging, forcing researchers to use invasive direct brain injections as a method of delivery [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR76">76</xref>].</p><p id="Par38">Building on these findings, Owusu-Yaw et al. [<xref ref-type="bibr" rid="CR66">66</xref>] assessed the efficacy of FUS with AAV9 in gene transfer using the zQ175 mouse model of HD. This animal model carries a human mHTT gene and exhibits many key characteristics of HD pathology, including mHTT aggregation, increased neuroinflammation, and blood-brain barrier (BBB) breakdown at later disease stages, which align with human HD pathophysiology. Researchers conducted a study using single-stranded AAV9 encoding a Green Fluorescent Protein (GFP) reporter gene in wild-type and zQ175 HD model mice at different disease stages (2, 6, and 12 months). Their study showed improved AAV9 delivery and similar efficacy in wild-type and HD mice, though GFP expression was reduced in older zQ175 mice. It is crucial to highlight that even in older zQ175 mice, FUS did not increase astrocytosis, which is the proliferation of astrocytes in response to injury, suggesting safety [<xref ref-type="bibr" rid="CR72">72</xref>].</p><p id="Par39">While the reduced GFP expression in older mice suggests that age and disease progression may influence the efficacy of this method, the overall findings underscore the potential of FUS as a non-invasive, precise tool for gene therapy. Generally, these studies in oligonucleotide-based therapies and targeted delivery methods with the ability to selectively silence the mHTT while minimizing the off-target effects represent a significant leap forward in the treatment of HD. Advancements that enhance the efficiency of siRNA and AAV therapies across the BBB through developing novel nanocarriers and improved FUS techniques would be welcomed. Furthermore, it is crucial to assess the safety and efficacy of these oligonucleotide-based therapies in humans and try to strike a balance between reducing mHTT levels and preserving the essential functions of the normal HTT protein. Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> summarizes the previously discussed preclinical studies on FUS-mediated treatments in HD.</p><p id="Par40">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of the preclinical trials on FUS-mediated BBB opening in HD [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study Name</th><th align="left">Purpose</th><th align="left">Therapeutic Agent</th><th align="left">Animal model used</th><th align="left">FUS Parameters</th><th align="left">Target Area</th><th align="left">Key Findings</th><th align="left">Safety Profile</th></tr></thead><tbody><tr><td align="left">Owusu-Yaw et al. [<xref ref-type="bibr" rid="CR66">66</xref>]</td><td align="left">To evaluate the efficacy of FUS-mediated delivery of AAV9-based gene therapy in 2-month-old WT mice and the zQ175 HD mouse model at 2-, 6-, and 12-months.</td><td align="left">AAV9-U6-miR10150-CBA-GFP vector</td><td align="left">zQ175 HDmouse models</td><td align="left"><p>Frequency: 690&#x000a0;kHz</p><p>Burst length: 10 ms</p><p>Repetition frequency: 1&#x000a0;Hz</p><p>Duration: 120&#x000a0;s</p><p>Pressure: 0.34&#x000a0;MPa</p></td><td align="left">Striatum and cortex</td><td align="left">- FUS Treatment Impact: Improved AAV9 delivery for all mouse groups.- GFP Expression: Strong GFP expression in neurons and astrocytes.- Delivery Efficacy: Similar efficacy in all WT and HD groups, except for zQ175 12-month cohort.</td><td align="left">Astrocytosis did not increase after FUS treatment, even within the zQ175 12-month group exhibiting higher baseline levels of GFAP&#x000b9; expression.</td></tr><tr><td align="left">Burgess et al. [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">To evaluate the non-invasive delivery of siRNA targeting mHTT to the right striatum using FUS and microbubbles, with the left striatum serving as the control.</td><td align="left">siRNA-HTT</td><td align="left">Wistar rats</td><td align="left"><p>Frequency: 558&#x000a0;kHz</p><p>Estimated in situ pressure: 0.3&#x000a0;MPa</p><p>Burst duration: 10 ms</p><p>Pulse repetition frequency: 1&#x000a0;Hz</p><p>Total exposure duration per sonication: 120&#x000a0;s</p><p>Sonications: Conducted twice, with a one-hour interval between sessions</p><p>Microbubble contrast agent: Definity<sup>&#x000ae;</sup> (0.02&#x000a0;ml/kg) injected immediately before sonication</p></td><td align="left">Striatum</td><td align="left">- A significant 32% decrease in HTT expression following delivery of siRNA-HTT to the striatum with FUS.- The reduction in HTT DNA was dose-dependent, with higher siRNA-HTT concentrations.- The reduction in HTT with siRNA-HTT was more pronounced as the extent of BBB disruption increased.</td><td align="left">No FUS-related adverse effects were reported. However, prolonged suppression of HTT may impair neuronal function, though a reduction of up to 30% appears to be tolerable.</td></tr><tr><td align="left">Lin et al. [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td align="left">To assess FUS-BBB opening for the delivery of a non-viral gene delivery system (LpDNA) containing both the pLuc-N3 and GDNF genes</td><td align="left">GDNFp-LPs</td><td align="left">R6/2 transgenic mouse models</td><td align="left"><p>Acoustic pressure: 0.33&#x000a0;MPa</p><p>Frequency: 500&#x000a0;kHz</p><p>Burst duration: 10 milliseconds</p><p>Pulse repetition frequency (PRF): 1&#x000a0;Hz</p><p>Duty cycle: 1%</p><p>Total exposure time: 30&#x000a0;s on the contralateral hemisphere and 60&#x000a0;s on the ipsilateral hemisphere</p><p>Microbubble (MB) dose: SonoVue<sup>&#x000ae;</sup> at 0.1&#x000a0;mg/kg</p></td><td align="left">Striatum and cortex</td><td align="left">- GDNF was successfully expressed at targeted sites following FUS, with significant amplification of gene expression.- Enhanced transduction: 5-fold increase in intensity 2 days after FUS + LpDNA vs. LpDNA alone.- FUS-induced BBB opening led to higher concentrations of both drugs and genes at the target sites, demonstrating the stability and repeatability of the technique.</td><td align="left">This study indicates the repeatability of FUS-mediated BBB opening, with no adverse events reported.</td></tr></tbody></table><table-wrap-foot><p>GFAP fluorescence intensity was quantified as a measure of the level of astrocyte activation.FUS: focused ultrasound; AAV9: adeno-associated virus serotype 9; WT: wild-type; HD: Huntington's disease; GFP: green fluorescent protein; GFAP: Glial fibrillary acidic protein; siRNA-HTT: small interfering RNA targeting Huntingtin; mHTT: mutant HTT; BBB: blood-brain barrier; GDNF: glial cell line-derived neurotrophic factor; LpDNA: liposomes containing plasmid DNA</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec7"><title>Discussion on Precision, Safety, and Efficacy of FUS</title><sec id="Sec8"><title>Precision and Safety</title><p id="Par41">Since the inception of FUS technology, its precision has been a focal point in research. Both spatial and temporal precisions are cornerstones in determining the applicability of various techniques. Studies dating back to the 1990s established that FUS could accurately target specific organs while sparing surrounding tissues, achieving a spatial precision of 250&#x02013;300 microns, roughly the size of 10 hepatocytes [<xref ref-type="bibr" rid="CR77">77</xref>]. A similar recent study on myocytes highlighted that the distance between affected and unaffected areas by FUS was inappreciable. This study showed that FUS can affect one half of a cell while preserving the other [<xref ref-type="bibr" rid="CR78">78</xref>]. Additionally, combining FUS with MRI, which is the standard approach now, has markedly enhanced its spatial accuracy [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>] given the invaluable insights provided by the imaging regarding sonication parameters and target boundaries [<xref ref-type="bibr" rid="CR81">81</xref>].</p><p id="Par42">Since 2001, when FUS was first demonstrated to safely and effectively open BBB in animal models [<xref ref-type="bibr" rid="CR49">49</xref>], its potential for human application has been increasingly recognized [<xref ref-type="bibr" rid="CR82">82</xref>]. Through the fast-track translation of the emerging technique, its safety is now established in humans as well. The technique shows no long-term deficits in BBB function or structure, creating a temporary opening that typically lasts up to 24&#x000a0;h [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR62">62</xref>&#x02013;<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. This provides a crucial window for drug administration, allowing therapeutic agents to reach the brain while ensuring the BBB returns to its normal state afterward. Moreover, there is repeated BBB opening with complete healing each time and no histological or physiological damage [<xref ref-type="bibr" rid="CR84">84</xref>].</p><p id="Par43">Clinical studies by Abrahao et al., Lipsman et al., Rezai et al., Mehta et al., and Gasca-Salas et al., have corroborated the safety of FUS in patients with neurodegenerative diseases such as AD, PD, and ALS, reporting no adverse effects such as intracranial hemorrhage, cognitive or neurological deficits, or physiological disruptions [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR62">62</xref>&#x02013;<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. FUS is notable for its high spatial specificity and non-invasive nature, along with the fact that the energy needed to open the BBB is three times lower than that required to damage tissue. These unique features enhance the safety profile of FUS, especially in treating conditions like HD, where preserving brain integrity is paramount [<xref ref-type="bibr" rid="CR85">85</xref>].</p><p id="Par44">However, there are some pre-clinical trials on the long-term adverse events and safety of repeated FUS application that reported minimal side effects and this should be considered despite the safe application in the clinical trials of neurodegenerative diseases given the chronic course of HD. For instance, a study on sheep receiving weekly FUS-mediated BBB openings over six weeks found no abnormalities or behavioral changes in any experimental animals, though a single animal exposed to higher acoustic pressures (0.58&#x000a0;MPa) experienced minor, localized cerebral hemorrhage [<xref ref-type="bibr" rid="CR86">86</xref>].</p><p id="Par45">Additional research has explored vascular implications of FUS. One study observed transient blood supply reductions in regions with BBB disruption, suggesting FUS may impact vascular integrity in certain cases [<xref ref-type="bibr" rid="CR87">87</xref>]. A transient hyperemic response in the unsonicated contralateral hemisphere also indicated a possible systemic response.</p><p id="Par46">Moreover, FUS-induced BBB disruption has been associated with transient inflammatory responses. Kovacs et al. reported elevated levels of pro-inflammatory molecules and activation of microglia and astrocytes following FUS, raising concerns about cumulative inflammatory effects from repeated treatments [<xref ref-type="bibr" rid="CR88">88</xref>]. McMahon and Hynynen further explored the acute inflammatory response following FUS-induced BBB permeability increase [<xref ref-type="bibr" rid="CR89">89</xref>]. They found that the inflammatory response was dependent on MB dose, suggesting that optimizing MBs administration could help minimize inflammatory risks.</p><p id="Par47">Clinical trials of FUS-mediated BBB opening in neurodegenerative diseases were supported by other preclinical studies that reported complete short- and long-term physical and functional safety profiles of its application in non-human primates such as rhesus macaques and others [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR91">91</xref>]. However, careful monitoring and optimizing its parameters are recommended during its administration in human patients.</p></sec><sec id="Sec9"><title>Efficacy of FUS and Challenges of Translation</title><p id="Par48">Preclinical trials on FUS-mediated BBB opening in HD models consistently demonstrate promising outcomes [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>], including increased brain concentrations of therapeutic agents, along with significant reductions in mHTT mRNA levels and abnormal cytoplasmic HTT protein aggregates. These findings align with similar preclinical studies on other neurodegenerative diseases, including ALS and AD [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>], as well as brain tumors like glioma and glioblastoma [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. Furthermore, FUS has shown the ability to lower the required drug dosage needed for achieving the desired therapeutic effect, potentially minimizing side effects while maximizing efficacy [<xref ref-type="bibr" rid="CR93">93</xref>].</p><p id="Par49">Currently, no clinical trials have been completed, are active, or are recruiting patients to investigate the impact of FUS-based BBB disruption specifically in HD patients. The only clinical intersection between FUS and HD to date is a trial (NCT02252380) examining FUS-mediated ablation of targeted brain regions for managing movement disorders, including HD, through HIFUS [<xref ref-type="bibr" rid="CR96">96</xref>].</p><p id="Par50">Despite promising preclinical data, several limitations hinder the clinical translation of FUS in other neurodegenerative diseases. These challenges encompass limited external validity of clinical trials due to small sample sizes, the lack of a clearly defined threshold for effective BBB opening in humans, and a lack of conclusive findings on the impact of MB factors and sonication parameters on BBB permeability and various brain regions [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR97">97</xref>].</p><p id="Par51">Regarding HD, biological challenges are another type of challenge that might be faced. Since HD involves neuroinflammatory processes and MBs may be associated with transient inflammatory responses [<xref ref-type="bibr" rid="CR89">89</xref>], it is essential to rigorously assess potential interactions between these inflammatory mechanisms before progressing to clinical trials. This is critical to ensure that FUS does not exacerbate the underlying pathology in HD patients. Further, the definite long-term consequences of BBB opening in humans is still unclear. Mehta et al., in their study on FUS-mediated BBB opening in AD patients, recommended long-term follow-up and post-mortem analyses of participants in FUS trials to gain a deeper understanding of the therapy&#x02019;s prolonged impact [<xref ref-type="bibr" rid="CR97">97</xref>]. Developing human-relevant in vitro models, such as those derived from induced pluripotent stem cells, may provide valuable insights into the specific responses of human BBB to FUS treatment in the context of HD. These models could help bridge the gap between animal studies and human clinical trials, accelerating the translation process while ensuring patient safety.</p></sec></sec><sec id="Sec10"><title>In vitro BBB Models and FUS Application in HD</title><p id="Par52">Human in vitro BBB models hold significant promise for translating preclinical findings regarding FUS applications in HD. These models typically consist of cells that replicate the structure of the human BBB, including the NVUs cultured on scaffolds that mimic the extracellular matrix [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par53">These in vitro BBB models are derived from human-induced pluripotent stem cells (hiPSCs), which are reprogrammed [<xref ref-type="bibr" rid="CR98">98</xref>] from somatic cells such as blood or skin cells using specific transcription factors [<xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. hiPSCs possess unlimited proliferative capacity and can be differentiated into mature cell types that closely resemble their in vivo counterparts. In the context of BBB models, hiPSCs can be engineered to carry genetic mutations associated with neurodegenerative diseases, thereby reflecting the pathological changes observed in the BBB [<xref ref-type="bibr" rid="CR101">101</xref>&#x02013;<xref ref-type="bibr" rid="CR105">105</xref>]. Consequently, these models can replicate the altered microvascular environment characteristic of neurodegenerative disorders. Furthermore, researchers can develop personalized BBB models for individual patients since hiPSCs can be generated from a patient&#x02019;s fibroblasts [<xref ref-type="bibr" rid="CR22">22</xref>]. This capability has spurred investigations into drug delivery systems within the context of neurodegenerative diseases, aided by advancements in differentiation protocols and the ability to accurately reflect the BBB environment in vitro.</p><p id="Par54">hiPSC-derived BBB models have been extensively utilized in FUS studies of neurodegenerative diseases other than HD [<xref ref-type="bibr" rid="CR106">106</xref>&#x02013;<xref ref-type="bibr" rid="CR108">108</xref>] because they not only replicate in vivo drug permeability but also allow for precise control over experimental conditions. The ability to manipulate FUS parameters, accurate quantification of BBB opening, and smooth high-throughput drug screening offered by these models make them well-suited for FUS applications [<xref ref-type="bibr" rid="CR109">109</xref>]. Additionally, in vitro BBB models allow for the exploration of sonication-associated effects at single-cell resolution, a level of detail that is not achievable in live human subjects [<xref ref-type="bibr" rid="CR40">40</xref>]. Recent research has elucidated the parameters of FUS and MBs relevant to both human patients and BBB models of neurodegenerative diseases. A comprehensive comparison of these parameters across in vitro BBB models and clinical studies involving patients with AD, ALS, and PD is detailed in the review by Wasielewska et al., which draws on results from three clinical trials and a study by Oikari et al. focusing on a BBB in vitro model [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR110">110</xref>].</p><sec id="Sec11"><title>Benefits of in vitro BBB Models for FUS in HD</title><p id="Par55">Current research faces significant challenges in identifying primary BBB dysfunctions in HD and elucidating their underlying mechanisms through animal models and postmortem tissues [<xref ref-type="bibr" rid="CR111">111</xref>]. In addition, understanding how FUS specifically exerts its effects is crucial for clinical translation, particularly given the complex pathophysiology and changes in brain microvascularity associated with HD [<xref ref-type="bibr" rid="CR111">111</xref>&#x02013;<xref ref-type="bibr" rid="CR113">113</xref>]. Personalized hiPSC-derived BBB models provide a promising solution for these two issues by reflecting the unique conditions of HD patients&#x02019; BBBs [<xref ref-type="bibr" rid="CR114">114</xref>]. Studies using HD in vitro BBB models have begun to investigate the impact of CAG repeat expansions on BBB properties, including transendothelial electrical resistance, receptor-mediated transcytosis, and responses to both physiological and pathological stressors, such as oxidative and osmotic stress [<xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR114">114</xref>]. Further studies have evaluated the permeability of HD-related drugs (e.g., arginine, verapamil, and vinblastine) through these models, contributing to our understanding of drug transport and BBB resilience under HD conditions [<xref ref-type="bibr" rid="CR112">112</xref>]. These advanced in vitro models can mitigate interspecies differences and bridge the gap between animal findings and clinical trials by providing individualized parameters for safer and more effective treatment strategies.</p><p id="Par56">Despite the insights gained from related neurodegenerative disease studies, the literature currently lacks research applying FUS in an HD in vitro BBB model. In contrast, over ten clinical trials have explored BBB opening through FUS in AD patients, where ongoing in vitro studies aim to address the limitations in these clinical trials. Most existing clinical trials have primarily focused on the safety and efficacy of FUS in BBB opening without assessing drug delivery efficacy due to a limited understanding of FUS mechanisms and their interactions with brain vasculature. For example, a recent study on an AD patient-derived in vitro BBB model demonstrated that FUS could enhance the permeability of a 5&#x000a0;kDa cargo molecule and revealed clinically relevant differences in post-treatment recovery durations between disease genotypes, as well as insights into how endothelial cells interact with pericytes and astrocytes that may influence the BBB&#x02019;s response to therapeutic ultrasound [<xref ref-type="bibr" rid="CR110">110</xref>]. These findings highlight the potential benefits of patient-specific BBB models in HD research, enhancing our understanding of FUS-induced permeability changes and promoting targeted therapeutic strategies for HD.</p><p id="Par57">By leveraging insights from in vitro BBB models, researchers can refine FUS protocols and drug delivery strategies tailored to individual patients, ultimately enhancing patient outcomes. These models may address limitations encountered in animal trials of FUS for HD by exploring the properties of BBB dysfunction associated with HD and optimizing parameters to ensure human tolerability for future clinical trials.</p></sec></sec><sec id="Sec12" sec-type="conclusion"><title>Conclusion</title><p id="Par58">FUS is a noninvasive technology that can cause a temporary opening of the BBB, allowing therapeutic molecules to enter the brain, and is particularly promising. This innovative method significantly increases the bioavailability of neuroprotective agents for HD improving therapeutic outcomes in animal models. Although preclinical studies have demonstrated encouraging results, the clinical application of FUS in HD is still in its infancy. However, as clinical trials begin to explore the safety and effectiveness of FUS in humans with other neurodegenerative diseases, this will bring us closer to transforming these discoveries into practical treatments of neurodegenerative diseases, including HD. This progress offers hope for significantly changing the course of the disease and improving the lives of those affected.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author Contributions</title><p>M.M.H: Conceived the idea for the study, developed the overall design and direction, and wrote all sections of the manuscript except for the section titled &#x0201c;FUS in HD: Preclinical Evidence&#x0201d; and the conclusion.A.A.I: Was responsible for creating all figures and tables included in the review and authored the section &#x0201c;FUS in HD: Preclinical Evidence.&#x0201c;A.B: Managed the references, prepared the manuscript according to journal guidelines, suggested related references, and drafted various sections of the manuscript. M.K: Provided supervision, revised the manuscript with critical insights, and drafted the abstract and conclusion sections, ensuring clarity and scientific rigor throughout the study.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p><p>The authors have no relevant financial or non-financial interests to disclose.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar3"><title>Ethical Approval</title><p id="Par59">The manuscript does not contain clinical studies or patient data.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing Interests</title><p id="Par60">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Scientific Image and Illustration Software| BioRender</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Huntington&#x02019;s Disease - Symptoms, Causes, Treatment| NORD</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Rojas NG, Cesarini ME, Peker G, Da Prat GA, Etcheverry JL, Gatto EM (2022) Review of Huntington&#x02019;s Disease: from basics to advances in diagnosis and treatment. J Neurol Res 12</mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>R</given-names></name><name><surname>Tabrizi</surname><given-names>SJ</given-names></name></person-group><article-title>Clinical features of Huntington&#x02019;s disease</article-title><source>Adv Exp Med Biol</source><year>2018</year><volume>1049</volume><fpage>1</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">29427096</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Ghosh R, Tabrizi SJ (2018) Clinical features of Huntington&#x02019;s disease. Adv Exp Med Biol 1049:1&#x02013;28<pub-id pub-id-type="pmid">29427096</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>FO</given-names></name></person-group><article-title>Huntington&#x02019;s disease</article-title><source>Lancet</source><year>2007</year><volume>369</volume><fpage>218</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">17240289</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Walker FO (2007) Huntington&#x02019;s disease. Lancet 369:218&#x02013;228<pub-id pub-id-type="pmid">17240289</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><collab>Huntington Study Group COHORT Investigators &#x00026;</collab><name><surname>Dorsey</surname><given-names>ER</given-names></name></person-group><article-title>Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e29522</fpage><pub-id pub-id-type="pmid">22359536</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Huntington Study Group COHORT Investigators &#x00026;, Dorsey ER (2012) Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. PLoS ONE 7:e29522<pub-id pub-id-type="pmid">22359536</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>GP</given-names></name><name><surname>Dorsey</surname><given-names>R</given-names></name><name><surname>Gusella</surname><given-names>JF</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Kay</surname><given-names>C</given-names></name><name><surname>Leavitt</surname><given-names>BR</given-names></name><name><surname>Nance</surname><given-names>M</given-names></name><name><surname>Ross</surname><given-names>CA</given-names></name><name><surname>Scahill</surname><given-names>RI</given-names></name><name><surname>Wetzel</surname><given-names>R</given-names></name><name><surname>Wild</surname><given-names>EJ</given-names></name><name><surname>Tabrizi</surname><given-names>SJ</given-names></name></person-group><article-title>Huntington disease</article-title><source>Nat Rev Dis Primers</source><year>2015</year><volume>1</volume><fpage>15005</fpage><pub-id pub-id-type="pmid">27188817</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ (2015) Huntington disease. Nat Rev Dis Primers 1:15005<pub-id pub-id-type="pmid">27188817</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Wyant</surname><given-names>KJ</given-names></name><name><surname>Ridder</surname><given-names>AJ</given-names></name><name><surname>Dayalu</surname><given-names>P</given-names></name></person-group><article-title>Huntington&#x02019;s Disease-Update on treatments</article-title><source>Curr Neurol Neurosci Rep</source><year>2017</year><volume>17</volume><fpage>33</fpage><pub-id pub-id-type="pmid">28324302</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Wyant KJ, Ridder AJ, Dayalu P (2017) Huntington&#x02019;s Disease-Update on treatments. Curr Neurol Neurosci Rep 17:33<pub-id pub-id-type="pmid">28324302</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Dumas</surname><given-names>EM</given-names></name><name><surname>van den Bogaard</surname><given-names>SJA</given-names></name><name><surname>Middelkoop</surname><given-names>HAM</given-names></name><name><surname>Roos</surname><given-names>RAC</given-names></name></person-group><article-title>A review of cognition in Huntington&#x02019;s disease</article-title><source>Front Biosci (Schol Ed)</source><year>2013</year><volume>5</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">23277034</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Dumas EM, van den Bogaard SJA, Middelkoop HAM, Roos RAC (2013) A review of cognition in Huntington&#x02019;s disease. Front Biosci (Schol Ed) 5:1&#x02013;18<pub-id pub-id-type="pmid">23277034</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Kumar A, Kumar V, Singh K, Kumar S, Kim Y-S, Lee Y-M, Kim J-J (2020) Therapeutic advances for Huntington&#x02019;s disease. Brain Sci 10</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Wellington CL, Leavitt BR, Hayden MR (2000) Huntington disease: new insights on the role of huntingtin cleavage. J Neural Transm 58(Suppl):1&#x02013;17</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">S&#x000e1;nchez-Pernaute R, Garc&#x000ed;a-Segura JM, del Barrio Alba A, Via&#x000f1;o J, de Y&#x000e9;benes JG (1999) Clinical correlation of striatal 1H MRS changes in Huntington&#x02019;s disease. Neurology 53:806&#x02013;812</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C (2009) Therapeutic interventions for disease progression in Huntington&#x02019;s disease. <italic>Cochrane Database Syst Rev</italic> 2009, CD006455</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Safety and tolerability of WVE-120102 in patients with Huntington&#x02019;s Disease (2017). <ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov">ClinicalTrials.gov</ext-link></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Safety and tolerability of WVE-120101 in patients with Huntington&#x02019;s Disease (2017). <ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov">ClinicalTrials.gov</ext-link></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">GENERATION HD2 A study to evaluate the safety, biomarkers, and efficacy of Tominersen compared with placebo in participants with Prodromal and Early Manifest Huntington&#x02019;s Disease (2023). <ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov">ClinicalTrials.gov</ext-link></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">A study to evaluate the efficacy and safety of Intrathecally Administered RO7234292 (RG6042) in participants with Manifest Huntington&#x02019;s Disease (2019). <ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov">ClinicalTrials.gov</ext-link></mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Kordasiewicz</surname><given-names>HB</given-names></name><name><surname>Stanek</surname><given-names>LM</given-names></name><name><surname>Wancewicz</surname><given-names>EV</given-names></name><name><surname>Mazur</surname><given-names>C</given-names></name><name><surname>McAlonis</surname><given-names>MM</given-names></name><name><surname>Pytel</surname><given-names>KA</given-names></name><name><surname>Artates</surname><given-names>JW</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>SH</given-names></name><name><surname>Shihabuddin</surname><given-names>LS</given-names></name><name><surname>Hung</surname><given-names>G</given-names></name><name><surname>Bennett</surname><given-names>CF</given-names></name><name><surname>Cleveland</surname><given-names>DW</given-names></name></person-group><article-title>Sustained therapeutic reversal of Huntington&#x02019;s disease by transient repression of huntingtin synthesis</article-title><source>Neuron</source><year>2012</year><volume>74</volume><fpage>1031</fpage><lpage>1044</lpage><pub-id pub-id-type="pmid">22726834</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, Hung G, Bennett CF, Cleveland DW (2012) Sustained therapeutic reversal of Huntington&#x02019;s disease by transient repression of huntingtin synthesis. Neuron 74:1031&#x02013;1044<pub-id pub-id-type="pmid">22726834</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>JL</given-names></name><name><surname>Pitzer</surname><given-names>MR</given-names></name><name><surname>Boudreau</surname><given-names>RL</given-names></name><name><surname>Dufour</surname><given-names>B</given-names></name><name><surname>Hobbs</surname><given-names>T</given-names></name><name><surname>Ojeda</surname><given-names>SR</given-names></name><name><surname>Davidson</surname><given-names>BL</given-names></name></person-group><article-title>Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington&#x02019;s disease</article-title><source>Mol Ther</source><year>2011</year><volume>19</volume><fpage>2152</fpage><lpage>2162</lpage><pub-id pub-id-type="pmid">22031240</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, Davidson BL (2011) Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington&#x02019;s disease. Mol Ther 19:2152&#x02013;2162<pub-id pub-id-type="pmid">22031240</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Marxreiter F, Stemick J, Kohl Z (2020) Huntingtin lowering strategies. Int J Mol Sci 21</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Culver</surname><given-names>BP</given-names></name><name><surname>Savas</surname><given-names>JN</given-names></name><name><surname>Park</surname><given-names>SK</given-names></name><name><surname>Choi</surname><given-names>JH</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Zeitlin</surname><given-names>SO</given-names></name><name><surname>Yates</surname><given-names>JR</given-names></name><name><surname>Tanese</surname><given-names>N</given-names></name></person-group><article-title>Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>21599</fpage><lpage>21614</lpage><pub-id pub-id-type="pmid">22556411</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Culver BP, Savas JN, Park SK, Choi JH, Zheng S, Zeitlin SO, Yates JR, Tanese N (2012) Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis. J Biol Chem 287:21599&#x02013;21614<pub-id pub-id-type="pmid">22556411</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Dragatsis</surname><given-names>I</given-names></name><name><surname>Levine</surname><given-names>MS</given-names></name><name><surname>Zeitlin</surname><given-names>S</given-names></name></person-group><article-title>Inactivation of hdh in the brain and testis results in progressive neurodegeneration and sterility in mice</article-title><source>Nat Genet</source><year>2000</year><volume>26</volume><fpage>300</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">11062468</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Dragatsis I, Levine MS, Zeitlin S (2000) Inactivation of hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26:300&#x02013;306<pub-id pub-id-type="pmid">11062468</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Gaertig</surname><given-names>MA</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X-J</given-names></name></person-group><article-title>Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis</article-title><source>Proc Natl Acad Sci USA</source><year>2016</year><volume>113</volume><fpage>3359</fpage><lpage>3364</lpage><pub-id pub-id-type="pmid">26951659</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Wang G, Liu X, Gaertig MA, Li S, Li X-J (2016) Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc Natl Acad Sci USA 113:3359&#x02013;3364<pub-id pub-id-type="pmid">26951659</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J-P</given-names></name><name><surname>Zeitlin</surname><given-names>SO</given-names></name></person-group><article-title>Is huntingtin dispensable in the adult brain?</article-title><source>J Huntingtons Dis</source><year>2017</year><volume>6</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">28339401</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Liu J-P, Zeitlin SO (2017) Is huntingtin dispensable in the adult brain? J Huntingtons Dis 6:1&#x02013;17<pub-id pub-id-type="pmid">28339401</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>KM</given-names></name></person-group><article-title>Recent advances in the treatment of Huntington&#x02019;s disease: targeting DNA and RNA</article-title><source>CNS Drugs</source><year>2020</year><volume>34</volume><fpage>219</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">31933283</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Shannon KM (2020) Recent advances in the treatment of Huntington&#x02019;s disease: targeting DNA and RNA. CNS Drugs 34:219&#x02013;228<pub-id pub-id-type="pmid">31933283</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Zuccato</surname><given-names>C</given-names></name><name><surname>Valenza</surname><given-names>M</given-names></name><name><surname>Cattaneo</surname><given-names>E</given-names></name></person-group><article-title>Molecular mechanisms and potential therapeutical targets in Huntington&#x02019;s disease</article-title><source>Physiol Rev</source><year>2010</year><volume>90</volume><fpage>905</fpage><lpage>981</lpage><pub-id pub-id-type="pmid">20664076</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington&#x02019;s disease. Physiol Rev 90:905&#x02013;981<pub-id pub-id-type="pmid">20664076</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Sweeney</surname><given-names>MD</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Montagne</surname><given-names>A</given-names></name><name><surname>Nelson</surname><given-names>AR</given-names></name><name><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group><article-title>Blood-brain barrier: from physiology to Disease and back</article-title><source>Physiol Rev</source><year>2019</year><volume>99</volume><fpage>21</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">30280653</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV (2019) Blood-brain barrier: from physiology to Disease and back. Physiol Rev 99:21&#x02013;78<pub-id pub-id-type="pmid">30280653</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Pardridge</surname><given-names>WM</given-names></name></person-group><article-title>The blood-brain barrier: bottleneck in brain drug development</article-title><source>NeuroRx</source><year>2005</year><volume>2</volume><fpage>3</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">15717053</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3&#x02013;14<pub-id pub-id-type="pmid">15717053</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>FY</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Woodle</surname><given-names>MC</given-names></name><name><surname>Zhong</surname><given-names>N</given-names></name><name><surname>Lu</surname><given-names>PY</given-names></name></person-group><article-title>Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque</article-title><source>Nat Med</source><year>2005</year><volume>11</volume><fpage>944</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">16116432</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Li B, Tang Q, Cheng D, Qin C, Xie FY, Wei Q, Xu J, Liu Y, Zheng B, Woodle MC, Zhong N, Lu PY (2005) Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 11:944&#x02013;951<pub-id pub-id-type="pmid">16116432</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Thakker</surname><given-names>DR</given-names></name><name><surname>Natt</surname><given-names>F</given-names></name><name><surname>H&#x000fc;sken</surname><given-names>D</given-names></name><name><surname>Maier</surname><given-names>R</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name><name><surname>van der Putten</surname><given-names>H</given-names></name><name><surname>Hoyer</surname><given-names>D</given-names></name><name><surname>Cryan</surname><given-names>JF</given-names></name></person-group><article-title>Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>17270</fpage><lpage>17275</lpage><pub-id pub-id-type="pmid">15569935</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Thakker DR, Natt F, H&#x000fc;sken D, Maier R, M&#x000fc;ller M, van der Putten H, Hoyer D, Cryan JF (2004) Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA 101:17270&#x02013;17275<pub-id pub-id-type="pmid">15569935</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Mendon&#x000e7;a</surname><given-names>MCP</given-names></name><name><surname>Cronin</surname><given-names>MF</given-names></name><name><surname>Cryan</surname><given-names>JF</given-names></name><name><surname>O&#x02019;Driscoll</surname><given-names>CM</given-names></name></person-group><article-title>Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model</article-title><source>Eur J Pharm Biopharm</source><year>2021</year><volume>169</volume><fpage>309</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">34793942</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Mendon&#x000e7;a MCP, Cronin MF, Cryan JF, O&#x02019;Driscoll CM (2021) Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model. Eur J Pharm Biopharm 169:309&#x02013;318<pub-id pub-id-type="pmid">34793942</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Querbes</surname><given-names>W</given-names></name><name><surname>Sah</surname><given-names>DW</given-names></name><name><surname>Hynynen</surname><given-names>K</given-names></name></person-group><article-title>Focused ultrasound for targeted delivery of siRNA and efficient knockdown of htt expression</article-title><source>J Control Release</source><year>2012</year><volume>163</volume><fpage>125</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">22921802</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Burgess A, Huang Y, Querbes W, Sah DW, Hynynen K (2012) Focused ultrasound for targeted delivery of siRNA and efficient knockdown of htt expression. J Control Release 163:125&#x02013;129<pub-id pub-id-type="pmid">22921802</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Hynynen</surname><given-names>K</given-names></name><name><surname>McDannold</surname><given-names>N</given-names></name><name><surname>Vykhodtseva</surname><given-names>N</given-names></name><name><surname>Jolesz</surname><given-names>FA</given-names></name></person-group><article-title>Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits</article-title><source>Radiology</source><year>2001</year><volume>220</volume><fpage>640</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">11526261</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA (2001) Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 220:640&#x02013;646<pub-id pub-id-type="pmid">11526261</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>SQ</given-names></name><name><surname>Staber</surname><given-names>PD</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Eliason</surname><given-names>SL</given-names></name><name><surname>Martins</surname><given-names>IH</given-names></name><name><surname>Mao</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Kotin</surname><given-names>RM</given-names></name><name><surname>Paulson</surname><given-names>HL</given-names></name><name><surname>Davidson</surname><given-names>BL</given-names></name></person-group><article-title>RNA interference improves motor and neuropathological abnormalities in a Huntington&#x02019;s disease mouse model</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>5820</fpage><lpage>5825</lpage><pub-id pub-id-type="pmid">15811941</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington&#x02019;s disease mouse model. Proc Natl Acad Sci USA 102:5820&#x02013;5825<pub-id pub-id-type="pmid">15811941</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Andreassen</surname><given-names>OA</given-names></name><name><surname>Dedeoglu</surname><given-names>A</given-names></name><name><surname>Ferrante</surname><given-names>RJ</given-names></name><name><surname>Jenkins</surname><given-names>BG</given-names></name><name><surname>Ferrante</surname><given-names>KL</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Friedlich</surname><given-names>A</given-names></name><name><surname>Browne</surname><given-names>SE</given-names></name><name><surname>Schilling</surname><given-names>G</given-names></name><name><surname>Borchelt</surname><given-names>DR</given-names></name><name><surname>Hersch</surname><given-names>SM</given-names></name><name><surname>Ross</surname><given-names>CA</given-names></name><name><surname>Beal</surname><given-names>MF</given-names></name></person-group><article-title>Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington&#x02019;s disease</article-title><source>Neurobiol Dis</source><year>2001</year><volume>8</volume><fpage>479</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">11447996</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF (2001) Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington&#x02019;s disease. Neurobiol Dis 8:479&#x02013;491<pub-id pub-id-type="pmid">11447996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Segarra</surname><given-names>M</given-names></name><name><surname>Aburto</surname><given-names>MR</given-names></name><name><surname>Acker-Palmer</surname><given-names>A</given-names></name></person-group><article-title>Blood-brain Barrier dynamics to maintain Brain Homeostasis</article-title><source>Trends Neurosci</source><year>2021</year><volume>44</volume><fpage>393</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">33423792</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Segarra M, Aburto MR, Acker-Palmer A (2021) Blood-brain Barrier dynamics to maintain Brain Homeostasis. Trends Neurosci 44:393&#x02013;405<pub-id pub-id-type="pmid">33423792</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>A</given-names></name><name><surname>Kaushik</surname><given-names>DK</given-names></name><name><surname>Lozinski</surname><given-names>BM</given-names></name><name><surname>Yong</surname><given-names>VW</given-names></name></person-group><article-title>Beyond barrier functions: roles of pericytes in homeostasis and regulation of neuroinflammation</article-title><source>J Neurosci Res</source><year>2020</year><volume>98</volume><fpage>2390</fpage><lpage>2405</lpage><pub-id pub-id-type="pmid">32815569</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Bhattacharya A, Kaushik DK, Lozinski BM, Yong VW (2020) Beyond barrier functions: roles of pericytes in homeostasis and regulation of neuroinflammation. J Neurosci Res 98:2390&#x02013;2405<pub-id pub-id-type="pmid">32815569</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>CW</given-names></name></person-group><article-title>Permeability of the blood-brain barrier: Molecular Mechanism of Transport of Drugs and physiologically important compounds</article-title><source>J Membr Biol</source><year>2015</year><volume>248</volume><fpage>651</fpage><lpage>669</lpage><pub-id pub-id-type="pmid">25675910</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Fong CW (2015) Permeability of the blood-brain barrier: Molecular Mechanism of Transport of Drugs and physiologically important compounds. J Membr Biol 248:651&#x02013;669<pub-id pub-id-type="pmid">25675910</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>SP</given-names></name><name><surname>Crone</surname><given-names>C</given-names></name></person-group><article-title>Electrical resistance of muscle capillary endothelium</article-title><source>Biophys J</source><year>1983</year><volume>42</volume><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">6601500</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Olesen SP, Crone C (1983) Electrical resistance of muscle capillary endothelium. Biophys J 42:31&#x02013;41<pub-id pub-id-type="pmid">6601500</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Wasielewska</surname><given-names>JM</given-names></name><name><surname>White</surname><given-names>AR</given-names></name></person-group><article-title>Focused Ultrasound-mediated drug delivery in humans - a path towards translation in neurodegenerative diseases</article-title><source>Pharm Res</source><year>2022</year><volume>39</volume><fpage>427</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">35257286</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Wasielewska JM, White AR (2022) Focused Ultrasound-mediated drug delivery in humans - a path towards translation in neurodegenerative diseases. Pharm Res 39:427&#x02013;439<pub-id pub-id-type="pmid">35257286</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Kusuhara</surname><given-names>H</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name></person-group><article-title>Active efflux across the blood-brain barrier: role of the solute carrier family</article-title><source>NeuroRx</source><year>2005</year><volume>2</volume><fpage>73</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">15717059</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Kusuhara H, Sugiyama Y (2005) Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2:73&#x02013;85<pub-id pub-id-type="pmid">15717059</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Redd</surname><given-names>TK</given-names></name><name><surname>Al-Khaled</surname><given-names>T</given-names></name><name><surname>Paul Chan</surname><given-names>RV</given-names></name><name><surname>Campbell</surname><given-names>JP</given-names></name><collab>American Academy of Ophthalmology Task Force on Academic Global Ophthalmology &#x00026; American Academy of Ophthalmology Task Force on Academic Global Ophthalmology</collab></person-group><article-title>Technology and innovation in global ophthalmology: the past, the potential, and a path forward</article-title><source>Int Ophthalmol Clin</source><year>2023</year><volume>63</volume><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">36598831</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Redd TK, Al-Khaled T, Paul Chan RV, Campbell JP, American Academy of Ophthalmology Task Force on Academic Global Ophthalmology &#x00026; American Academy of Ophthalmology Task Force on Academic Global Ophthalmology (2023) Technology and innovation in global ophthalmology: the past, the potential, and a path forward. Int Ophthalmol Clin 63:25&#x02013;32<pub-id pub-id-type="pmid">36598831</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Bhattacharjee</surname><given-names>AK</given-names></name><name><surname>Kondoh</surname><given-names>T</given-names></name><name><surname>Nagashima</surname><given-names>T</given-names></name><name><surname>Tamaki</surname><given-names>N</given-names></name></person-group><article-title>Synergistic effect of cold mannitol and na(+)/Ca(2+) exchange blocker on blood-brain barrier opening</article-title><source>Biochem Biophys Res Commun</source><year>2002</year><volume>291</volume><fpage>669</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">11855842</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Ikeda M, Bhattacharjee AK, Kondoh T, Nagashima T, Tamaki N (2002) Synergistic effect of cold mannitol and na(+)/Ca(2+) exchange blocker on blood-brain barrier opening. Biochem Biophys Res Commun 291:669&#x02013;674<pub-id pub-id-type="pmid">11855842</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Nagashima</surname><given-names>T</given-names></name><name><surname>Bhattacharjee</surname><given-names>AK</given-names></name><name><surname>Kondoh</surname><given-names>T</given-names></name><name><surname>Kohmura</surname><given-names>E</given-names></name><name><surname>Tamaki</surname><given-names>N</given-names></name></person-group><article-title>Quantitative analysis of hyperosmotic and hypothermic blood-brain barrier opening</article-title><source>Acta Neurochir Suppl</source><year>2003</year><volume>86</volume><fpage>559</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">14753506</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Ikeda M, Nagashima T, Bhattacharjee AK, Kondoh T, Kohmura E, Tamaki N (2003) Quantitative analysis of hyperosmotic and hypothermic blood-brain barrier opening. Acta Neurochir Suppl 86:559&#x02013;563<pub-id pub-id-type="pmid">14753506</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Doolittle</surname><given-names>ND</given-names></name><name><surname>Miner</surname><given-names>ME</given-names></name><name><surname>Hall</surname><given-names>WA</given-names></name><name><surname>Siegal</surname><given-names>T</given-names></name><name><surname>Jerome</surname><given-names>E</given-names></name><name><surname>Osztie</surname><given-names>E</given-names></name><name><surname>McAllister</surname><given-names>LD</given-names></name><name><surname>Bubalo</surname><given-names>JS</given-names></name><name><surname>Kraemer</surname><given-names>DF</given-names></name><name><surname>Fortin</surname><given-names>D</given-names></name><name><surname>Nixon</surname><given-names>R</given-names></name><name><surname>Muldoon</surname><given-names>LL</given-names></name><name><surname>Neuwelt</surname><given-names>EA</given-names></name></person-group><article-title>Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors</article-title><source>Cancer</source><year>2000</year><volume>88</volume><fpage>637</fpage><lpage>647</lpage><pub-id pub-id-type="pmid">10649259</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Doolittle ND, Miner ME, Hall WA, Siegal T, Jerome E, Osztie E, McAllister LD, Bubalo JS, Kraemer DF, Fortin D, Nixon R, Muldoon LL, Neuwelt EA (2000) Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88:637&#x02013;647<pub-id pub-id-type="pmid">10649259</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>NJ</given-names></name><name><surname>Romero</surname><given-names>IA</given-names></name></person-group><article-title>Transporting therapeutics across the blood-brain barrier</article-title><source>Mol Med Today</source><year>1996</year><volume>2</volume><fpage>106</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">8796867</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Abbott NJ, Romero IA (1996) Transporting therapeutics across the blood-brain barrier. Mol Med Today 2:106&#x02013;113<pub-id pub-id-type="pmid">8796867</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Kroll</surname><given-names>RA</given-names></name><name><surname>Neuwelt</surname><given-names>EA</given-names></name></person-group><article-title>Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means</article-title><source>Neurosurgery</source><year>1998</year><volume>42</volume><fpage>1083</fpage><lpage>1099</lpage><pub-id pub-id-type="pmid">9588554</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Kroll RA, Neuwelt EA (1998) Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42:1083&#x02013;1099 discussion 1099<pub-id pub-id-type="pmid">9588554</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Vykhodtseva</surname><given-names>NI</given-names></name><name><surname>Hynynen</surname><given-names>K</given-names></name><name><surname>Damianou</surname><given-names>C</given-names></name></person-group><article-title>Histologic effects of high intensity pulsed ultrasound exposure with subharmonic emission in rabbit brain in vivo</article-title><source>Ultrasound Med Biol</source><year>1995</year><volume>21</volume><fpage>969</fpage><lpage>979</lpage><pub-id pub-id-type="pmid">7491751</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Vykhodtseva NI, Hynynen K, Damianou C (1995) Histologic effects of high intensity pulsed ultrasound exposure with subharmonic emission in rabbit brain in vivo. Ultrasound Med Biol 21:969&#x02013;979<pub-id pub-id-type="pmid">7491751</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Clement</surname><given-names>GT</given-names></name><name><surname>Hynynen</surname><given-names>K</given-names></name></person-group><article-title>A non-invasive method for focusing ultrasound through the human skull</article-title><source>Phys Med Biol</source><year>2002</year><volume>47</volume><fpage>1219</fpage><lpage>1236</lpage><pub-id pub-id-type="pmid">12030552</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Clement GT, Hynynen K (2002) A non-invasive method for focusing ultrasound through the human skull. Phys Med Biol 47:1219&#x02013;1236<pub-id pub-id-type="pmid">12030552</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Rouhi N, Chakeri Z, Ghorbani Nejad B, Rahimzadegan M, Rafi Khezri M, Kamali H, Nosrati R (2024) A comprehensive review of advanced focused ultrasound (FUS) microbubbles-mediated treatment of Alzheimer&#x02019;s disease. Heliyon 10, e37533</mixed-citation></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>McDannold</surname><given-names>N</given-names></name><name><surname>Vykhodtseva</surname><given-names>N</given-names></name><name><surname>Hynynen</surname><given-names>K</given-names></name></person-group><article-title>Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption</article-title><source>Ultrasound Med Biol</source><year>2008</year><volume>34</volume><fpage>930</fpage><lpage>937</lpage><pub-id pub-id-type="pmid">18294757</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">McDannold N, Vykhodtseva N, Hynynen K (2008) Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption. Ultrasound Med Biol 34:930&#x02013;937<pub-id pub-id-type="pmid">18294757</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Sheikov</surname><given-names>N</given-names></name><name><surname>McDannold</surname><given-names>N</given-names></name><name><surname>Jolesz</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>Y-Z</given-names></name><name><surname>Tam</surname><given-names>K</given-names></name><name><surname>Hynynen</surname><given-names>K</given-names></name></person-group><article-title>Brain arterioles show more active vesicular transport of blood-borne tracer molecules than capillaries and venules after focused ultrasound-evoked opening of the blood-brain barrier</article-title><source>Ultrasound Med Biol</source><year>2006</year><volume>32</volume><fpage>1399</fpage><lpage>1409</lpage><pub-id pub-id-type="pmid">16965980</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Sheikov N, McDannold N, Jolesz F, Zhang Y-Z, Tam K, Hynynen K (2006) Brain arterioles show more active vesicular transport of blood-borne tracer molecules than capillaries and venules after focused ultrasound-evoked opening of the blood-brain barrier. Ultrasound Med Biol 32:1399&#x02013;1409<pub-id pub-id-type="pmid">16965980</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K-T</given-names></name><name><surname>Wei</surname><given-names>K-C</given-names></name><name><surname>Liu</surname><given-names>H-L</given-names></name></person-group><article-title>Theranostic strategy of focused Ultrasound Induced blood-brain barrier opening for CNS Disease Treatment</article-title><source>Front Pharmacol</source><year>2019</year><volume>10</volume><fpage>86</fpage><pub-id pub-id-type="pmid">30792657</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Chen K-T, Wei K-C, Liu H-L (2019) Theranostic strategy of focused Ultrasound Induced blood-brain barrier opening for CNS Disease Treatment. Front Pharmacol 10:86<pub-id pub-id-type="pmid">30792657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>J</given-names></name><name><surname>Kong</surname><given-names>C</given-names></name><name><surname>Cho</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Koh</surname><given-names>CS</given-names></name><name><surname>Yoon</surname><given-names>M-S</given-names></name><name><surname>Na</surname><given-names>YC</given-names></name><name><surname>Chang</surname><given-names>WS</given-names></name><name><surname>Chang</surname><given-names>JW</given-names></name></person-group><article-title>Focused ultrasound-mediated noninvasive blood-brain barrier modulation: preclinical examination of efficacy and safety in various sonication parameters</article-title><source>Neurosurg Focus</source><year>2018</year><volume>44</volume><fpage>E15</fpage><pub-id pub-id-type="pmid">29385915</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Shin J, Kong C, Cho JS, Lee J, Koh CS, Yoon M-S, Na YC, Chang WS, Chang JW (2018) Focused ultrasound-mediated noninvasive blood-brain barrier modulation: preclinical examination of efficacy and safety in various sonication parameters. Neurosurg Focus 44:E15<pub-id pub-id-type="pmid">29385915</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Hsu Y-H, Lee W-C, Chu S-S, Chao M-E, Wu K-S, Liu R-S, Wong T-T (2022) Influence of Acoustic Parameters and Sonication Schemes on Transcranial Blood-Brain Barrier Disruption Induced by Pulsed Weakly Focused Ultrasound. <italic>Pharmaceutics</italic> 14</mixed-citation></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Gasca-Salas</surname><given-names>C</given-names></name><name><surname>Fern&#x000e1;ndez-Rodr&#x000ed;guez</surname><given-names>B</given-names></name><name><surname>Pineda-Pardo</surname><given-names>JA</given-names></name><name><surname>Rodr&#x000ed;guez-Rojas</surname><given-names>R</given-names></name><name><surname>Obeso</surname><given-names>I</given-names></name><name><surname>Hern&#x000e1;ndez-Fern&#x000e1;ndez</surname><given-names>F</given-names></name><name><surname>Del &#x000c1;lamo</surname><given-names>M</given-names></name><name><surname>Mata</surname><given-names>D</given-names></name><name><surname>Guida</surname><given-names>P</given-names></name><name><surname>Ord&#x000e1;s-Bandera</surname><given-names>C</given-names></name><name><surname>Montero-Roblas</surname><given-names>JI</given-names></name><name><surname>Mart&#x000ed;nez-Fern&#x000e1;ndez</surname><given-names>R</given-names></name><name><surname>Foffani</surname><given-names>G</given-names></name><name><surname>Rachmilevitch</surname><given-names>I</given-names></name><name><surname>Obeso</surname><given-names>JA</given-names></name></person-group><article-title>Blood-brain barrier opening with focused ultrasound in Parkinson&#x02019;s disease dementia</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>779</fpage><pub-id pub-id-type="pmid">33536430</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Gasca-Salas C, Fern&#x000e1;ndez-Rodr&#x000ed;guez B, Pineda-Pardo JA, Rodr&#x000ed;guez-Rojas R, Obeso I, Hern&#x000e1;ndez-Fern&#x000e1;ndez F, Del &#x000c1;lamo M, Mata D, Guida P, Ord&#x000e1;s-Bandera C, Montero-Roblas JI, Mart&#x000ed;nez-Fern&#x000e1;ndez R, Foffani G, Rachmilevitch I, Obeso JA (2021) Blood-brain barrier opening with focused ultrasound in Parkinson&#x02019;s disease dementia. Nat Commun 12:779<pub-id pub-id-type="pmid">33536430</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Alkins</surname><given-names>R</given-names></name><name><surname>Schwartz</surname><given-names>ML</given-names></name><name><surname>Hynynen</surname><given-names>K</given-names></name></person-group><article-title>Opening the blood-brain barrier with MR Imaging-guided focused Ultrasound: preclinical testing on a trans-human Skull Porcine Model</article-title><source>Radiology</source><year>2017</year><volume>282</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">27420647</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Huang Y, Alkins R, Schwartz ML, Hynynen K (2017) Opening the blood-brain barrier with MR Imaging-guided focused Ultrasound: preclinical testing on a trans-human Skull Porcine Model. Radiology 282:123&#x02013;130<pub-id pub-id-type="pmid">27420647</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Dong</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>Clinical application of magnetic resonance-guided focused ultrasound in Parkinson&#x02019;s disease: a meta-analysis of randomized clinical trials</article-title><source>Neurol Sci</source><year>2021</year><volume>42</volume><fpage>3595</fpage><lpage>3604</lpage><pub-id pub-id-type="pmid">34216307</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Ge Y, Wang Z, Gu F, Yang X, Chen Z, Dong W, Wang Z (2021) Clinical application of magnetic resonance-guided focused ultrasound in Parkinson&#x02019;s disease: a meta-analysis of randomized clinical trials. Neurol Sci 42:3595&#x02013;3604<pub-id pub-id-type="pmid">34216307</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>WJ</given-names></name><name><surname>Lipsman</surname><given-names>N</given-names></name><name><surname>Ondo</surname><given-names>WG</given-names></name><name><surname>Ghanouni</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>YG</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Hynynen</surname><given-names>K</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name><name><surname>Shah</surname><given-names>BB</given-names></name><name><surname>Huss</surname><given-names>D</given-names></name><name><surname>Dallapiazza</surname><given-names>RF</given-names></name><name><surname>Gwinn</surname><given-names>R</given-names></name><name><surname>Witt</surname><given-names>J</given-names></name><name><surname>Ro</surname><given-names>S</given-names></name><name><surname>Eisenberg</surname><given-names>HM</given-names></name><name><surname>Fishman</surname><given-names>PS</given-names></name><name><surname>Gandhi</surname><given-names>D</given-names></name><name><surname>Halpern</surname><given-names>CH</given-names></name><name><surname>Chuang</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>JW</given-names></name></person-group><article-title>A randomized trial of focused ultrasound thalamotomy for essential tremor</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>730</fpage><lpage>739</lpage><pub-id pub-id-type="pmid">27557301</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Elias WJ, Lipsman N, Ondo WG, Ghanouni P, Kim YG, Lee W, Schwartz M, Hynynen K, Lozano AM, Shah BB, Huss D, Dallapiazza RF, Gwinn R, Witt J, Ro S, Eisenberg HM, Fishman PS, Gandhi D, Halpern CH, Chuang R, Chang JW (2016) A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med 375:730&#x02013;739<pub-id pub-id-type="pmid">27557301</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>H</given-names></name><name><surname>Lockwood</surname><given-names>D</given-names></name><name><surname>Mason</surname><given-names>EJ</given-names></name><name><surname>Obusez</surname><given-names>E</given-names></name><name><surname>Poturalski</surname><given-names>M</given-names></name><name><surname>Rammo</surname><given-names>R</given-names></name><name><surname>Nagel</surname><given-names>SJ</given-names></name><name><surname>Jones</surname><given-names>SE</given-names></name></person-group><article-title>Clinical intervention using focused ultrasound (FUS) stimulation of the brain in diverse neurological disorders</article-title><source>Front Neurol</source><year>2022</year><volume>13</volume><fpage>880814</fpage><pub-id pub-id-type="pmid">35614924</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Baek H, Lockwood D, Mason EJ, Obusez E, Poturalski M, Rammo R, Nagel SJ, Jones SE (2022) Clinical intervention using focused ultrasound (FUS) stimulation of the brain in diverse neurological disorders. Front Neurol 13:880814<pub-id pub-id-type="pmid">35614924</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>RI</given-names></name><name><surname>Ranjan</surname><given-names>M</given-names></name><name><surname>Haut</surname><given-names>MW</given-names></name><name><surname>Carpenter</surname><given-names>JS</given-names></name><name><surname>Rezai</surname><given-names>AR</given-names></name></person-group><article-title>Focused ultrasound for neurodegenerative diseases</article-title><source>Magn Reson Imaging Clin N Am</source><year>2024</year><volume>32</volume><fpage>681</fpage><lpage>698</lpage><pub-id pub-id-type="pmid">39322357</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Mehta RI, Ranjan M, Haut MW, Carpenter JS, Rezai AR (2024) Focused ultrasound for neurodegenerative diseases. Magn Reson Imaging Clin N Am 32:681&#x02013;698<pub-id pub-id-type="pmid">39322357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Lipsman</surname><given-names>N</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Bethune</surname><given-names>AJ</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Lam</surname><given-names>B</given-names></name><name><surname>Masellis</surname><given-names>M</given-names></name><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>Heyn</surname><given-names>C</given-names></name><name><surname>Aubert</surname><given-names>I</given-names></name><name><surname>Boutet</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>GS</given-names></name><name><surname>Hynynen</surname><given-names>K</given-names></name><name><surname>Black</surname><given-names>SE</given-names></name></person-group><article-title>Blood-brain barrier opening in Alzheimer&#x02019;s disease using MR-guided focused ultrasound</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><fpage>2336</fpage><pub-id pub-id-type="pmid">30046032</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Lipsman N, Meng Y, Bethune AJ, Huang Y, Lam B, Masellis M, Herrmann N, Heyn C, Aubert I, Boutet A, Smith GS, Hynynen K, Black SE (2018) Blood-brain barrier opening in Alzheimer&#x02019;s disease using MR-guided focused ultrasound. Nat Commun 9:2336<pub-id pub-id-type="pmid">30046032</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Rezai</surname><given-names>AR</given-names></name><name><surname>Ranjan</surname><given-names>M</given-names></name><name><surname>D&#x02019;Haese</surname><given-names>P-F</given-names></name><name><surname>Haut</surname><given-names>MW</given-names></name><name><surname>Carpenter</surname><given-names>J</given-names></name><name><surname>Najib</surname><given-names>U</given-names></name><name><surname>Mehta</surname><given-names>RI</given-names></name><name><surname>Chazen</surname><given-names>JL</given-names></name><name><surname>Zibly</surname><given-names>Z</given-names></name><name><surname>Yates</surname><given-names>JR</given-names></name><name><surname>Hodder</surname><given-names>SL</given-names></name><name><surname>Kaplitt</surname><given-names>M</given-names></name></person-group><article-title>Noninvasive hippocampal blood-brain barrier opening in Alzheimer&#x02019;s disease with focused ultrasound</article-title><source>Proc Natl Acad Sci USA</source><year>2020</year><volume>117</volume><fpage>9180</fpage><lpage>9182</lpage><pub-id pub-id-type="pmid">32284421</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Rezai AR, Ranjan M, D&#x02019;Haese P-F, Haut MW, Carpenter J, Najib U, Mehta RI, Chazen JL, Zibly Z, Yates JR, Hodder SL, Kaplitt M (2020) Noninvasive hippocampal blood-brain barrier opening in Alzheimer&#x02019;s disease with focused ultrasound. Proc Natl Acad Sci USA 117:9180&#x02013;9182<pub-id pub-id-type="pmid">32284421</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Abrahao</surname><given-names>A</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Llinas</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name><name><surname>Mainprize</surname><given-names>T</given-names></name><name><surname>Aubert</surname><given-names>I</given-names></name><name><surname>Heyn</surname><given-names>C</given-names></name><name><surname>Black</surname><given-names>SE</given-names></name><name><surname>Hynynen</surname><given-names>K</given-names></name><name><surname>Lipsman</surname><given-names>N</given-names></name><name><surname>Zinman</surname><given-names>L</given-names></name></person-group><article-title>First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>4373</fpage><pub-id pub-id-type="pmid">31558719</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Abrahao A, Meng Y, Llinas M, Huang Y, Hamani C, Mainprize T, Aubert I, Heyn C, Black SE, Hynynen K, Lipsman N, Zinman L (2019) First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound. Nat Commun 10:4373<pub-id pub-id-type="pmid">31558719</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C-Y</given-names></name><name><surname>Tsai</surname><given-names>C-H</given-names></name><name><surname>Feng</surname><given-names>L-Y</given-names></name><name><surname>Chai</surname><given-names>W-Y</given-names></name><name><surname>Lin</surname><given-names>C-J</given-names></name><name><surname>Huang</surname><given-names>C-Y</given-names></name><name><surname>Wei</surname><given-names>K-C</given-names></name><name><surname>Yeh</surname><given-names>C-K</given-names></name><name><surname>Chen</surname><given-names>C-M</given-names></name><name><surname>Liu</surname><given-names>H-L</given-names></name></person-group><article-title>Focused ultrasound-induced blood brain-barrier opening enhanced vascular permeability for GDNF delivery in Huntington&#x02019;s disease mouse model</article-title><source>Brain Stimulat</source><year>2019</year><volume>12</volume><fpage>1143</fpage><lpage>1150</lpage></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Lin C-Y, Tsai C-H, Feng L-Y, Chai W-Y, Lin C-J, Huang C-Y, Wei K-C, Yeh C-K, Chen C-M, Liu H-L (2019) Focused ultrasound-induced blood brain-barrier opening enhanced vascular permeability for GDNF delivery in Huntington&#x02019;s disease mouse model. Brain Stimulat 12:1143&#x02013;1150</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="other">Owusu-Yaw BS, Zhang Y, Garrett L, Yao A, Shing K, Batista AR, Sena-Esteves M, Upadhyay J, Kegel-Gleason K, Todd N (2024) Focused Ultrasound-Mediated Disruption of the Blood-Brain Barrier for AAV9 Delivery in a Mouse Model of Huntington&#x02019;s Disease. <italic>Pharmaceutics</italic> 16</mixed-citation></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Ib&#x000e1;&#x000f1;ez</surname><given-names>CF</given-names></name><name><surname>Paratcha</surname><given-names>G</given-names></name><name><surname>Ledda</surname><given-names>F</given-names></name></person-group><article-title>RET-independent signaling by GDNF ligands and GFR&#x003b1; receptors</article-title><source>Cell Tissue Res</source><year>2020</year><volume>382</volume><fpage>71</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">32737575</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Ib&#x000e1;&#x000f1;ez CF, Paratcha G, Ledda F (2020) RET-independent signaling by GDNF ligands and GFR&#x003b1; receptors. Cell Tissue Res 382:71&#x02013;82<pub-id pub-id-type="pmid">32737575</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Kells</surname><given-names>AP</given-names></name><name><surname>Fong</surname><given-names>DM</given-names></name><name><surname>Dragunow</surname><given-names>M</given-names></name><name><surname>During</surname><given-names>MJ</given-names></name><name><surname>Young</surname><given-names>D</given-names></name><name><surname>Connor</surname><given-names>B</given-names></name></person-group><article-title>AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease</article-title><source>Mol Ther</source><year>2004</year><volume>9</volume><fpage>682</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">15120329</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Kells AP, Fong DM, Dragunow M, During MJ, Young D, Connor B (2004) AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 9:682&#x02013;688<pub-id pub-id-type="pmid">15120329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><mixed-citation publication-type="other">Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, Lozano AM, Penn RD, Simpson RK, Stacy M, Wooten GF, ICV GDNF Study Group, Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60:69&#x02013;73</mixed-citation></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Kordower</surname><given-names>JH</given-names></name><name><surname>Palfi</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>EY</given-names></name><name><surname>Ma</surname><given-names>SY</given-names></name><name><surname>Sendera</surname><given-names>T</given-names></name><name><surname>Cochran</surname><given-names>EJ</given-names></name><name><surname>Cochran</surname><given-names>EJ</given-names></name><name><surname>Mufson</surname><given-names>EJ</given-names></name><name><surname>Penn</surname><given-names>R</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Comella</surname><given-names>CD</given-names></name></person-group><article-title>Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson&#x02019;s disease</article-title><source>Ann Neurol</source><year>1999</year><volume>46</volume><fpage>419</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">10482276</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, Cochran EJ, Mufson EJ, Penn R, Goetz CG, Comella CD (1999) Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson&#x02019;s disease. Ann Neurol 46:419&#x02013;424<pub-id pub-id-type="pmid">10482276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>MM</given-names></name><name><surname>Bahal</surname><given-names>R</given-names></name><name><surname>Rasmussen</surname><given-names>TP</given-names></name><name><surname>Manautou</surname><given-names>JE</given-names></name><name><surname>Zhong</surname><given-names>X-B</given-names></name></person-group><article-title>The growth of siRNA-based therapeutics: updated clinical studies</article-title><source>Biochem Pharmacol</source><year>2021</year><volume>189</volume><fpage>114432</fpage><pub-id pub-id-type="pmid">33513339</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong X-B (2021) The growth of siRNA-based therapeutics: updated clinical studies. Biochem Pharmacol 189:114432<pub-id pub-id-type="pmid">33513339</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Aguiar</surname><given-names>S</given-names></name><name><surname>van der Gaag</surname><given-names>B</given-names></name><name><surname>Cortese</surname><given-names>FAB</given-names></name></person-group><article-title>RNAi mechanisms in Huntington&#x02019;s disease therapy: siRNA versus shRNA</article-title><source>Transl Neurodegener</source><year>2017</year><volume>6</volume><fpage>30</fpage><pub-id pub-id-type="pmid">29209494</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Aguiar S, van der Gaag B, Cortese FAB (2017) RNAi mechanisms in Huntington&#x02019;s disease therapy: siRNA versus shRNA. Transl Neurodegener 6:30<pub-id pub-id-type="pmid">29209494</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y-L</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wada</surname><given-names>E</given-names></name><name><surname>Murata</surname><given-names>M</given-names></name><name><surname>Wada</surname><given-names>K</given-names></name><name><surname>Kanazawa</surname><given-names>I</given-names></name></person-group><article-title>Clinico-pathological rescue of a model mouse of Huntington&#x02019;s disease by siRNA</article-title><source>Neurosci Res</source><year>2005</year><volume>53</volume><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">16095740</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Wang Y-L, Liu W, Wada E, Murata M, Wada K, Kanazawa I (2005) Clinico-pathological rescue of a model mouse of Huntington&#x02019;s disease by siRNA. Neurosci Res 53:241&#x02013;249<pub-id pub-id-type="pmid">16095740</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Mendonca</surname><given-names>CA</given-names></name><name><surname>Yukselen</surname><given-names>O</given-names></name><name><surname>Muneeruddin</surname><given-names>K</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Kucukural</surname><given-names>A</given-names></name><name><surname>Shaffer</surname><given-names>SA</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name></person-group><article-title>AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice</article-title><source>Nature</source><year>2022</year><volume>604</volume><fpage>343</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">35322228</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Wang J, Zhang Y, Mendonca CA, Yukselen O, Muneeruddin K, Ren L, Liang J, Zhou C, Xie J, Li J, Jiang Z, Kucukural A, Shaffer SA, Gao G, Wang D (2022) AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice. Nature 604:343&#x02013;348<pub-id pub-id-type="pmid">35322228</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Pupo</surname><given-names>A</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>A</given-names></name><name><surname>Low</surname><given-names>SH</given-names></name><name><surname>Fran&#x000e7;ois</surname><given-names>A</given-names></name><name><surname>Su&#x000e1;rez-Amar&#x000e1;n</surname><given-names>L</given-names></name><name><surname>Samulski</surname><given-names>RJ</given-names></name></person-group><article-title>AAV vectors: the Rubik&#x02019;s cube of human gene therapy</article-title><source>Mol Ther</source><year>2022</year><volume>30</volume><fpage>3515</fpage><lpage>3541</lpage><pub-id pub-id-type="pmid">36203359</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Pupo A, Fern&#x000e1;ndez A, Low SH, Fran&#x000e7;ois A, Su&#x000e1;rez-Amar&#x000e1;n L, Samulski RJ (2022) AAV vectors: the Rubik&#x02019;s cube of human gene therapy. Mol Ther 30:3515&#x02013;3541<pub-id pub-id-type="pmid">36203359</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Evers</surname><given-names>MM</given-names></name><name><surname>Miniarikova</surname><given-names>J</given-names></name><name><surname>Juhas</surname><given-names>S</given-names></name><name><surname>Vall&#x000e8;s</surname><given-names>A</given-names></name><name><surname>Bohuslavova</surname><given-names>B</given-names></name><name><surname>Juhasova</surname><given-names>J</given-names></name><name><surname>Skalnikova</surname><given-names>HK</given-names></name><name><surname>Vodicka</surname><given-names>P</given-names></name><name><surname>Valekova</surname><given-names>I</given-names></name><name><surname>Brouwers</surname><given-names>C</given-names></name><name><surname>Blits</surname><given-names>B</given-names></name><name><surname>Lubelski</surname><given-names>J</given-names></name><name><surname>Kovarova</surname><given-names>H</given-names></name><name><surname>Ellederova</surname><given-names>Z</given-names></name><name><surname>van Deventer</surname><given-names>SJ</given-names></name><name><surname>Petry</surname><given-names>H</given-names></name><name><surname>Motlik</surname><given-names>J</given-names></name><name><surname>Konstantinova</surname><given-names>P</given-names></name></person-group><article-title>AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington&#x02019;s Disease Minipig Model</article-title><source>Mol Ther</source><year>2018</year><volume>26</volume><fpage>2163</fpage><lpage>2177</lpage><pub-id pub-id-type="pmid">30007561</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Evers MM, Miniarikova J, Juhas S, Vall&#x000e8;s A, Bohuslavova B, Juhasova J, Skalnikova HK, Vodicka P, Valekova I, Brouwers C, Blits B, Lubelski J, Kovarova H, Ellederova Z, van Deventer SJ, Petry H, Motlik J, Konstantinova P (2018) AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington&#x02019;s Disease Minipig Model. Mol Ther 26:2163&#x02013;2177<pub-id pub-id-type="pmid">30007561</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>ter Haar</surname><given-names>GR</given-names></name><name><surname>Robertson</surname><given-names>D</given-names></name></person-group><article-title>Tissue destruction with focused ultrasound in vivo</article-title><source>Eur Urol</source><year>1993</year><volume>23</volume><issue>Suppl 1</issue><fpage>8</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">8513833</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">ter Haar GR, Robertson D (1993) Tissue destruction with focused ultrasound in vivo. Eur Urol 23(Suppl 1):8&#x02013;11<pub-id pub-id-type="pmid">8513833</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y-F</given-names></name></person-group><article-title>High intensity focused ultrasound in clinical tumor ablation</article-title><source>World J Clin Oncol</source><year>2011</year><volume>2</volume><fpage>8</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">21603311</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Zhou Y-F (2011) High intensity focused ultrasound in clinical tumor ablation. World J Clin Oncol 2:8&#x02013;27<pub-id pub-id-type="pmid">21603311</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Grasso</surname><given-names>G</given-names></name><name><surname>Torregrossa</surname><given-names>F</given-names></name><name><surname>Noto</surname><given-names>M</given-names></name><name><surname>Bruno</surname><given-names>E</given-names></name><name><surname>Feraco</surname><given-names>P</given-names></name><name><surname>Buscemi</surname><given-names>F</given-names></name><name><surname>Bartolotta</surname><given-names>TV</given-names></name><name><surname>Gagliardo</surname><given-names>C</given-names></name></person-group><article-title>MR-guided focused ultrasound-induced blood-brain barrier opening for brain metastasis: a review</article-title><source>Neurosurg Focus</source><year>2023</year><volume>55</volume><fpage>E11</fpage><pub-id pub-id-type="pmid">37527681</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Grasso G, Torregrossa F, Noto M, Bruno E, Feraco P, Buscemi F, Bartolotta TV, Gagliardo C (2023) MR-guided focused ultrasound-induced blood-brain barrier opening for brain metastasis: a review. Neurosurg Focus 55:E11<pub-id pub-id-type="pmid">37527681</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Bachu</surname><given-names>VS</given-names></name><name><surname>Kedda</surname><given-names>J</given-names></name><name><surname>Suk</surname><given-names>I</given-names></name><name><surname>Green</surname><given-names>JJ</given-names></name><name><surname>Tyler</surname><given-names>B</given-names></name></person-group><article-title>High-intensity focused Ultrasound: a review of mechanisms and clinical applications</article-title><source>Ann Biomed Eng</source><year>2021</year><volume>49</volume><fpage>1975</fpage><lpage>1991</lpage><pub-id pub-id-type="pmid">34374945</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Bachu VS, Kedda J, Suk I, Green JJ, Tyler B (2021) High-intensity focused Ultrasound: a review of mechanisms and clinical applications. Ann Biomed Eng 49:1975&#x02013;1991<pub-id pub-id-type="pmid">34374945</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><mixed-citation publication-type="other">Gagliardo C, Cannella R, D&#x02019;Angelo C, Toia P, Salvaggio G, Feraco P, Marrale M, Iacopino DG, D&#x02019;Amelio M, La Tona G, La Grutta L, Midiri M (2021) Transcranial Magnetic Resonance Imaging-Guided Focused Ultrasound with a 1.5 Tesla Scanner: A Prospective Intraindividual Comparison Study of Intraoperative Imaging. <italic>Brain Sci</italic> 11</mixed-citation></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>J</given-names></name><name><surname>Kong</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>BY</given-names></name><name><surname>Sim</surname><given-names>J</given-names></name><name><surname>Koh</surname><given-names>CS</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Na</surname><given-names>YC</given-names></name><name><surname>Suh</surname><given-names>SW</given-names></name><name><surname>Chang</surname><given-names>WS</given-names></name><name><surname>Chang</surname><given-names>JW</given-names></name></person-group><article-title>Focused ultrasound-induced blood-brain barrier opening improves adult hippocampal neurogenesis and cognitive function in a cholinergic degeneration dementia rat model</article-title><source>Alzheimers Res Ther</source><year>2019</year><volume>11</volume><fpage>110</fpage><pub-id pub-id-type="pmid">31881998</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Shin J, Kong C, Lee J, Choi BY, Sim J, Koh CS, Park M, Na YC, Suh SW, Chang WS, Chang JW (2019) Focused ultrasound-induced blood-brain barrier opening improves adult hippocampal neurogenesis and cognitive function in a cholinergic degeneration dementia rat model. Alzheimers Res Ther 11:110<pub-id pub-id-type="pmid">31881998</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>RI</given-names></name><name><surname>Carpenter</surname><given-names>JS</given-names></name><name><surname>Mehta</surname><given-names>RI</given-names></name><name><surname>Haut</surname><given-names>MW</given-names></name><name><surname>Ranjan</surname><given-names>M</given-names></name><name><surname>Najib</surname><given-names>U</given-names></name><name><surname>Lockman</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>D&#x02019;haese</surname><given-names>P-F</given-names></name><name><surname>Rezai</surname><given-names>AR</given-names></name></person-group><article-title>Blood-brain barrier opening with MRI-guided focused Ultrasound elicits meningeal venous permeability in humans with early Alzheimer Disease</article-title><source>Radiology</source><year>2021</year><volume>298</volume><fpage>654</fpage><lpage>662</lpage><pub-id pub-id-type="pmid">33399511</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Mehta RI, Carpenter JS, Mehta RI, Haut MW, Ranjan M, Najib U, Lockman P, Wang P, D&#x02019;haese P-F, Rezai AR (2021) Blood-brain barrier opening with MRI-guided focused Ultrasound elicits meningeal venous permeability in humans with early Alzheimer Disease. Radiology 298:654&#x02013;662<pub-id pub-id-type="pmid">33399511</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>McDannold</surname><given-names>N</given-names></name><name><surname>Arvanitis</surname><given-names>CD</given-names></name><name><surname>Vykhodtseva</surname><given-names>N</given-names></name><name><surname>Livingstone</surname><given-names>MS</given-names></name></person-group><article-title>Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><fpage>3652</fpage><lpage>3663</lpage><pub-id pub-id-type="pmid">22552291</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS (2012) Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res 72:3652&#x02013;3663<pub-id pub-id-type="pmid">22552291</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Pelekanos</surname><given-names>M</given-names></name><name><surname>Leinenga</surname><given-names>G</given-names></name><name><surname>Odabaee</surname><given-names>M</given-names></name><name><surname>Odabaee</surname><given-names>M</given-names></name><name><surname>Saifzadeh</surname><given-names>S</given-names></name><name><surname>Steck</surname><given-names>R</given-names></name><name><surname>G&#x000f6;tz</surname><given-names>J</given-names></name></person-group><article-title>Establishing sheep as an experimental species to validate ultrasound-mediated blood-brain barrier opening for potential therapeutic interventions</article-title><source>Theranostics</source><year>2018</year><volume>8</volume><fpage>2583</fpage><lpage>2602</lpage><pub-id pub-id-type="pmid">29721100</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Pelekanos M, Leinenga G, Odabaee M, Odabaee M, Saifzadeh S, Steck R, G&#x000f6;tz J (2018) Establishing sheep as an experimental species to validate ultrasound-mediated blood-brain barrier opening for potential therapeutic interventions. Theranostics 8:2583&#x02013;2602<pub-id pub-id-type="pmid">29721100</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Croce</surname><given-names>P</given-names></name><name><surname>Cammalleri</surname><given-names>A</given-names></name><name><surname>Foley</surname><given-names>L</given-names></name><name><surname>Tsao</surname><given-names>AL</given-names></name><name><surname>Yoo</surname><given-names>S-S</given-names></name></person-group><article-title>Localized blood-brain barrier opening in Ovine Model using image-guided Transcranial focused Ultrasound</article-title><source>Ultrasound Med Biol</source><year>2019</year><volume>45</volume><fpage>2391</fpage><lpage>2404</lpage><pub-id pub-id-type="pmid">31217090</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Yoon K, Lee W, Chen E, Lee JE, Croce P, Cammalleri A, Foley L, Tsao AL, Yoo S-S (2019) Localized blood-brain barrier opening in Ovine Model using image-guided Transcranial focused Ultrasound. Ultrasound Med Biol 45:2391&#x02013;2404<pub-id pub-id-type="pmid">31217090</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>C-H</given-names></name><name><surname>Liu</surname><given-names>H-L</given-names></name><name><surname>Huang</surname><given-names>C-Y</given-names></name><name><surname>Ma</surname><given-names>Y-J</given-names></name><name><surname>Yen</surname><given-names>T-C</given-names></name><name><surname>Yeh</surname><given-names>C-K</given-names></name></person-group><article-title>Detection of intracerebral hemorrhage and transient blood-supply shortage in focused-ultrasound-induced blood-brain barrier disruption by ultrasound imaging</article-title><source>Ultrasound Med Biol</source><year>2012</year><volume>38</volume><fpage>1372</fpage><lpage>1382</lpage><pub-id pub-id-type="pmid">22579546</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Fan C-H, Liu H-L, Huang C-Y, Ma Y-J, Yen T-C, Yeh C-K (2012) Detection of intracerebral hemorrhage and transient blood-supply shortage in focused-ultrasound-induced blood-brain barrier disruption by ultrasound imaging. Ultrasound Med Biol 38:1372&#x02013;1382<pub-id pub-id-type="pmid">22579546</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>ZI</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Jikaria</surname><given-names>N</given-names></name><name><surname>Qureshi</surname><given-names>F</given-names></name><name><surname>Milo</surname><given-names>B</given-names></name><name><surname>Lewis</surname><given-names>BK</given-names></name><name><surname>Bresler</surname><given-names>M</given-names></name><name><surname>Burks</surname><given-names>SR</given-names></name><name><surname>Frank</surname><given-names>JA</given-names></name></person-group><article-title>Disrupting the blood-brain barrier by focused ultrasound induces sterile inflammation</article-title><source>Proc Natl Acad Sci USA</source><year>2017</year><volume>114</volume><fpage>E75</fpage><lpage>E84</lpage><pub-id pub-id-type="pmid">27994152</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Kovacs ZI, Kim S, Jikaria N, Qureshi F, Milo B, Lewis BK, Bresler M, Burks SR, Frank JA (2017) Disrupting the blood-brain barrier by focused ultrasound induces sterile inflammation. Proc Natl Acad Sci USA 114:E75&#x02013;E84<pub-id pub-id-type="pmid">27994152</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname><given-names>D</given-names></name><name><surname>Hynynen</surname><given-names>K</given-names></name></person-group><article-title>Acute Inflammatory Response following increased blood-brain Barrier Permeability Induced by Focused Ultrasound is dependent on Microbubble Dose</article-title><source>Theranostics</source><year>2017</year><volume>7</volume><fpage>3989</fpage><lpage>4000</lpage><pub-id pub-id-type="pmid">29109793</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">McMahon D, Hynynen K (2017) Acute Inflammatory Response following increased blood-brain Barrier Permeability Induced by Focused Ultrasound is dependent on Microbubble Dose. Theranostics 7:3989&#x02013;4000<pub-id pub-id-type="pmid">29109793</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Downs</surname><given-names>ME</given-names></name><name><surname>Buch</surname><given-names>A</given-names></name><name><surname>Sierra</surname><given-names>C</given-names></name><name><surname>Karakatsani</surname><given-names>ME</given-names></name><name><surname>Teichert</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Konofagou</surname><given-names>EE</given-names></name><name><surname>Ferrera</surname><given-names>VP</given-names></name></person-group><article-title>Long-term safety of repeated blood-brain barrier opening via focused Ultrasound with Microbubbles in Non-human Primates performing a cognitive Task</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0125911</fpage><pub-id pub-id-type="pmid">25945493</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Downs ME, Buch A, Sierra C, Karakatsani ME, Teichert T, Chen S, Konofagou EE, Ferrera VP (2015) Long-term safety of repeated blood-brain barrier opening via focused Ultrasound with Microbubbles in Non-human Primates performing a cognitive Task. PLoS ONE 10:e0125911<pub-id pub-id-type="pmid">25945493</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>McDannold</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Supko</surname><given-names>JG</given-names></name><name><surname>Power</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Vykhodtseva</surname><given-names>N</given-names></name><name><surname>Golby</surname><given-names>AJ</given-names></name><name><surname>Reardon</surname><given-names>DA</given-names></name></person-group><article-title>Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><fpage>8766</fpage><pub-id pub-id-type="pmid">32472017</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">McDannold N, Zhang Y, Supko JG, Power C, Sun T, Vykhodtseva N, Golby AJ, Reardon DA (2020) Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system. Sci Rep 10:8766<pub-id pub-id-type="pmid">32472017</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Ultrasound-enhanced brain delivery of edaravone provides additive amelioration on disease progression in an ALS mouse model</article-title><source>Brain Stimulat</source><year>2023</year><volume>16</volume><fpage>628</fpage><lpage>641</lpage></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Shen Y, Zhang J, Xu Y, Sun S, Chen K, Chen S, Yang X, Chen X (2023) Ultrasound-enhanced brain delivery of edaravone provides additive amelioration on disease progression in an ALS mouse model. Brain Stimulat 16:628&#x02013;641</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Jord&#x000e3;o</surname><given-names>JF</given-names></name><name><surname>Ayala-Grosso</surname><given-names>CA</given-names></name><name><surname>Markham</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Chopra</surname><given-names>R</given-names></name><name><surname>McLaurin</surname><given-names>J</given-names></name><name><surname>Hynynen</surname><given-names>K</given-names></name><name><surname>Aubert</surname><given-names>I</given-names></name></person-group><article-title>Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer&#x02019;s disease</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><fpage>e10549</fpage><pub-id pub-id-type="pmid">20485502</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Jord&#x000e3;o JF, Ayala-Grosso CA, Markham K, Huang Y, Chopra R, McLaurin J, Hynynen K, Aubert I (2010) Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer&#x02019;s disease. PLoS ONE 5:e10549<pub-id pub-id-type="pmid">20485502</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Treat</surname><given-names>LH</given-names></name><name><surname>McDannold</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Vykhodtseva</surname><given-names>N</given-names></name><name><surname>Hynynen</surname><given-names>K</given-names></name></person-group><article-title>Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma</article-title><source>Ultrasound Med Biol</source><year>2012</year><volume>38</volume><fpage>1716</fpage><lpage>1725</lpage><pub-id pub-id-type="pmid">22818878</pub-id>
</element-citation><mixed-citation id="mc-CR94" publication-type="journal">Treat LH, McDannold N, Zhang Y, Vykhodtseva N, Hynynen K (2012) Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma. Ultrasound Med Biol 38:1716&#x02013;1725<pub-id pub-id-type="pmid">22818878</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Chevaleyre</surname><given-names>C</given-names></name><name><surname>Novell</surname><given-names>A</given-names></name><name><surname>Tournier</surname><given-names>N</given-names></name><name><surname>Dauba</surname><given-names>A</given-names></name><name><surname>Dubois</surname><given-names>S</given-names></name><name><surname>Kereselidze</surname><given-names>D</given-names></name><name><surname>Selingue</surname><given-names>E</given-names></name><name><surname>Jego</surname><given-names>B</given-names></name><name><surname>Maill&#x000e8;re</surname><given-names>B</given-names></name><name><surname>Larrat</surname><given-names>B</given-names></name><name><surname>Nozach</surname><given-names>H</given-names></name><name><surname>Truillet</surname><given-names>C</given-names></name></person-group><article-title>Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction</article-title><source>Theranostics</source><year>2023</year><volume>13</volume><fpage>5584</fpage><lpage>5596</lpage><pub-id pub-id-type="pmid">37908736</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Chevaleyre C, Novell A, Tournier N, Dauba A, Dubois S, Kereselidze D, Selingue E, Jego B, Maill&#x000e8;re B, Larrat B, Nozach H, Truillet C (2023) Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction. Theranostics 13:5584&#x02013;5596<pub-id pub-id-type="pmid">37908736</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Fasano</surname><given-names>A</given-names></name><name><surname>Llinas</surname><given-names>M</given-names></name><name><surname>Munhoz</surname><given-names>RP</given-names></name><name><surname>Hlasny</surname><given-names>E</given-names></name><name><surname>Kucharczyk</surname><given-names>W</given-names></name><name><surname>Lozano</surname><given-names>AM</given-names></name></person-group><article-title>MRI-guided focused ultrasound thalamotomy in non-ET tremor syndromes</article-title><source>Neurology</source><year>2017</year><volume>89</volume><fpage>771</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">28747452</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Fasano A, Llinas M, Munhoz RP, Hlasny E, Kucharczyk W, Lozano AM (2017) MRI-guided focused ultrasound thalamotomy in non-ET tremor syndromes. Neurology 89:771&#x02013;775<pub-id pub-id-type="pmid">28747452</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>RI</given-names></name><name><surname>Carpenter</surname><given-names>JS</given-names></name><name><surname>Mehta</surname><given-names>RI</given-names></name><name><surname>Haut</surname><given-names>MW</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Ranjan</surname><given-names>M</given-names></name><name><surname>Najib</surname><given-names>U</given-names></name><name><surname>D&#x02019;Haese</surname><given-names>P-F</given-names></name><name><surname>Rezai</surname><given-names>AR</given-names></name></person-group><article-title>Ultrasound-mediated blood-brain barrier opening uncovers an intracerebral perivenous fluid network in persons with Alzheimer&#x02019;s disease</article-title><source>Fluids Barriers CNS</source><year>2023</year><volume>20</volume><fpage>46</fpage><pub-id pub-id-type="pmid">37328855</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Mehta RI, Carpenter JS, Mehta RI, Haut MW, Wang P, Ranjan M, Najib U, D&#x02019;Haese P-F, Rezai AR (2023) Ultrasound-mediated blood-brain barrier opening uncovers an intracerebral perivenous fluid network in persons with Alzheimer&#x02019;s disease. Fluids Barriers CNS 20:46<pub-id pub-id-type="pmid">37328855</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><mixed-citation publication-type="other">Wu Y-C, Sonninen T-M, Peltonen S, Koistinaho J, Lehtonen &#x00160; (2021) Blood-brain barrier and neurodegenerative diseases-modeling with iPSC-Derived brain cells. Int J Mol Sci 22</mixed-citation></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Yamanaka</surname><given-names>S</given-names></name></person-group><article-title>Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors</article-title><source>Cell</source><year>2006</year><volume>126</volume><fpage>663</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">16904174</pub-id>
</element-citation><mixed-citation id="mc-CR99" publication-type="journal">Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663&#x02013;676<pub-id pub-id-type="pmid">16904174</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Teshigawara</surname><given-names>R</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Kameda</surname><given-names>M</given-names></name><name><surname>Tada</surname><given-names>T</given-names></name></person-group><article-title>Mechanism of human somatic reprogramming to iPS cell</article-title><source>Lab Invest</source><year>2017</year><volume>97</volume><fpage>1152</fpage><lpage>1157</lpage><pub-id pub-id-type="pmid">28530648</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Teshigawara R, Cho J, Kameda M, Tada T (2017) Mechanism of human somatic reprogramming to iPS cell. Lab Invest 97:1152&#x02013;1157<pub-id pub-id-type="pmid">28530648</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>C</given-names></name></person-group><article-title>Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application</article-title><source>Blood Res</source><year>2014</year><volume>49</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">24724061</pub-id>
</element-citation><mixed-citation id="mc-CR101" publication-type="journal">Kim C (2014) Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application. Blood Res 49:7&#x02013;14<pub-id pub-id-type="pmid">24724061</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>N</given-names></name><name><surname>Rao</surname><given-names>MS</given-names></name></person-group><article-title>A review of the methods for human iPSC derivation</article-title><source>Methods Mol Biol</source><year>2013</year><volume>997</volume><fpage>23</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">23546745</pub-id>
</element-citation><mixed-citation id="mc-CR102" publication-type="journal">Malik N, Rao MS (2013) A review of the methods for human iPSC derivation. Methods Mol Biol 997:23&#x02013;33<pub-id pub-id-type="pmid">23546745</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Oksanen</surname><given-names>M</given-names></name><name><surname>Petersen</surname><given-names>AJ</given-names></name><name><surname>Naumenko</surname><given-names>N</given-names></name><name><surname>Puttonen</surname><given-names>K</given-names></name><name><surname>Lehtonen</surname><given-names>&#x00160;</given-names></name><name><surname>Gubert Oliv&#x000e9;</surname><given-names>M</given-names></name><name><surname>Shakirzyanova</surname><given-names>A</given-names></name><name><surname>Leskel&#x000e4;</surname><given-names>S</given-names></name><name><surname>Saraj&#x000e4;rvi</surname><given-names>T</given-names></name><name><surname>Viitanen</surname><given-names>M</given-names></name><name><surname>Rinne</surname><given-names>JO</given-names></name><name><surname>Hiltunen</surname><given-names>M</given-names></name><name><surname>Haapasalo</surname><given-names>A</given-names></name><name><surname>Giniatullin</surname><given-names>R</given-names></name><name><surname>Tavi</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>S-C</given-names></name><name><surname>Kanninen</surname><given-names>KM</given-names></name><name><surname>H&#x000e4;m&#x000e4;l&#x000e4;inen</surname><given-names>RH</given-names></name><name><surname>Koistinaho</surname><given-names>J</given-names></name></person-group><article-title>PSEN1 mutant iPSC-Derived model reveals severe Astrocyte Pathology in Alzheimer&#x02019;s Disease</article-title><source>Stem Cell Rep</source><year>2017</year><volume>9</volume><fpage>1885</fpage><lpage>1897</lpage></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Oksanen M, Petersen AJ, Naumenko N, Puttonen K, Lehtonen &#x00160;, Gubert Oliv&#x000e9; M, Shakirzyanova A, Leskel&#x000e4; S, Saraj&#x000e4;rvi T, Viitanen M, Rinne JO, Hiltunen M, Haapasalo A, Giniatullin R, Tavi P, Zhang S-C, Kanninen KM, H&#x000e4;m&#x000e4;l&#x000e4;inen RH, Koistinaho J (2017) PSEN1 mutant iPSC-Derived model reveals severe Astrocyte Pathology in Alzheimer&#x02019;s Disease. Stem Cell Rep 9:1885&#x02013;1897</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Hern&#x000e1;ndez</surname><given-names>D</given-names></name><name><surname>Rooney</surname><given-names>LA</given-names></name><name><surname>Daniszewski</surname><given-names>M</given-names></name><name><surname>Gulluyan</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>HH</given-names></name><name><surname>Cook</surname><given-names>AL</given-names></name><name><surname>Hewitt</surname><given-names>AW</given-names></name><name><surname>P&#x000e9;bay</surname><given-names>A</given-names></name></person-group><article-title>Culture variabilities of human iPSC-Derived cerebral organoids are a major issue for the Modelling of Phenotypes Observed in Alzheimer&#x02019;s Disease</article-title><source>Stem Cell Rev Rep</source><year>2022</year><volume>18</volume><fpage>718</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">33725267</pub-id>
</element-citation><mixed-citation id="mc-CR104" publication-type="journal">Hern&#x000e1;ndez D, Rooney LA, Daniszewski M, Gulluyan L, Liang HH, Cook AL, Hewitt AW, P&#x000e9;bay A (2022) Culture variabilities of human iPSC-Derived cerebral organoids are a major issue for the Modelling of Phenotypes Observed in Alzheimer&#x02019;s Disease. Stem Cell Rev Rep 18:718&#x02013;731<pub-id pub-id-type="pmid">33725267</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name><surname>Katt</surname><given-names>ME</given-names></name><name><surname>Mayo</surname><given-names>LN</given-names></name><name><surname>Ellis</surname><given-names>SE</given-names></name><name><surname>Mahairaki</surname><given-names>V</given-names></name><name><surname>Rothstein</surname><given-names>JD</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Searson</surname><given-names>PC</given-names></name></person-group><article-title>The role of mutations associated with familial neurodegenerative disorders on blood-brain barrier function in an iPSC model</article-title><source>Fluids Barriers CNS</source><year>2019</year><volume>16</volume><fpage>20</fpage><pub-id pub-id-type="pmid">31303172</pub-id>
</element-citation><mixed-citation id="mc-CR105" publication-type="journal">Katt ME, Mayo LN, Ellis SE, Mahairaki V, Rothstein JD, Cheng L, Searson PC (2019) The role of mutations associated with familial neurodegenerative disorders on blood-brain barrier function in an iPSC model. Fluids Barriers CNS 16:20<pub-id pub-id-type="pmid">31303172</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name><surname>Wasielewska</surname><given-names>JM</given-names></name><name><surname>Chaves</surname><given-names>JCS</given-names></name><name><surname>Cabral-da-Silva</surname><given-names>MC</given-names></name><name><surname>Pecoraro</surname><given-names>M</given-names></name><name><surname>Viljoen</surname><given-names>SJ</given-names></name><name><surname>Nguyen</surname><given-names>TH</given-names></name><name><surname>Bella</surname><given-names>VL</given-names></name><name><surname>Oikari</surname><given-names>LE</given-names></name><name><surname>Ooi</surname><given-names>L</given-names></name><name><surname>White</surname><given-names>AR</given-names></name></person-group><article-title>A patient-derived amyotrophic lateral sclerosis blood-brain barrier model for focused ultrasound-mediated anti-TDP-43 antibody delivery</article-title><source>Fluids Barriers CNS</source><year>2024</year><volume>21</volume><fpage>65</fpage><pub-id pub-id-type="pmid">39138578</pub-id>
</element-citation><mixed-citation id="mc-CR106" publication-type="journal">Wasielewska JM, Chaves JCS, Cabral-da-Silva MC, Pecoraro M, Viljoen SJ, Nguyen TH, Bella VL, Oikari LE, Ooi L, White AR (2024) A patient-derived amyotrophic lateral sclerosis blood-brain barrier model for focused ultrasound-mediated anti-TDP-43 antibody delivery. Fluids Barriers CNS 21:65<pub-id pub-id-type="pmid">39138578</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Wasielewska</surname><given-names>JM</given-names></name><name><surname>Chaves</surname><given-names>JCS</given-names></name><name><surname>Johnston</surname><given-names>RL</given-names></name><name><surname>Milton</surname><given-names>LA</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Leinenga</surname><given-names>G</given-names></name><name><surname>Nisbet</surname><given-names>RM</given-names></name><name><surname>P&#x000e9;bay</surname><given-names>A</given-names></name><name><surname>G&#x000f6;tz</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>AR</given-names></name><name><surname>Oikari</surname><given-names>LE</given-names></name></person-group><article-title>A sporadic Alzheimer&#x02019;s blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-tau antibodies</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><fpage>6826</fpage><lpage>6847</lpage><pub-id pub-id-type="pmid">36276649</pub-id>
</element-citation><mixed-citation id="mc-CR107" publication-type="journal">Wasielewska JM, Chaves JCS, Johnston RL, Milton LA, Hern&#x000e1;ndez D, Chen L, Song J, Lee W, Leinenga G, Nisbet RM, P&#x000e9;bay A, G&#x000f6;tz J, White AR, Oikari LE (2022) A sporadic Alzheimer&#x02019;s blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-tau antibodies. Theranostics 12:6826&#x02013;6847<pub-id pub-id-type="pmid">36276649</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><mixed-citation publication-type="other">Chaves JCS, Wasielewska JM, Cun&#x000ed;-L&#x000f3;pez C, Rantanen LM, Lee S, Koistinaho J, White AR, Oikari LE (2024) Alzheimer&#x02019;s disease brain endothelial-like cells reveal differential drug transporter expression and modulation by potentially therapeutic focused ultrasound. Neurotherapeutics 21, e00299</mixed-citation></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name><surname>Roux</surname><given-names>GL</given-names></name><name><surname>Jarray</surname><given-names>R</given-names></name><name><surname>Guyot</surname><given-names>A-C</given-names></name><name><surname>Pavoni</surname><given-names>S</given-names></name><name><surname>Costa</surname><given-names>N</given-names></name><name><surname>Th&#x000e9;odoro</surname><given-names>F</given-names></name><name><surname>Nassor</surname><given-names>F</given-names></name><name><surname>Pruvost</surname><given-names>A</given-names></name><name><surname>Tournier</surname><given-names>N</given-names></name><name><surname>Kiyan</surname><given-names>Y</given-names></name><name><surname>Langer</surname><given-names>O</given-names></name><name><surname>Yates</surname><given-names>F</given-names></name><name><surname>Deslys</surname><given-names>JP</given-names></name><name><surname>Mabondzo</surname><given-names>A</given-names></name></person-group><article-title>Proof-of-Concept Study of Drug Brain Permeability between in vivo human brain and an in Vitro iPSCs-Human blood-brain barrier model</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><fpage>16310</fpage><pub-id pub-id-type="pmid">31690750</pub-id>
</element-citation><mixed-citation id="mc-CR109" publication-type="journal">Roux GL, Jarray R, Guyot A-C, Pavoni S, Costa N, Th&#x000e9;odoro F, Nassor F, Pruvost A, Tournier N, Kiyan Y, Langer O, Yates F, Deslys JP, Mabondzo A (2019) Proof-of-Concept Study of Drug Brain Permeability between in vivo human brain and an in Vitro iPSCs-Human blood-brain barrier model. Sci Rep 9:16310<pub-id pub-id-type="pmid">31690750</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name><surname>Oikari</surname><given-names>LE</given-names></name><name><surname>Pandit</surname><given-names>R</given-names></name><name><surname>Stewart</surname><given-names>R</given-names></name><name><surname>Cun&#x000ed;-L&#x000f3;pez</surname><given-names>C</given-names></name><name><surname>Quek</surname><given-names>H</given-names></name><name><surname>Sutharsan</surname><given-names>R</given-names></name><name><surname>Rantanen</surname><given-names>LM</given-names></name><name><surname>Oksanen</surname><given-names>M</given-names></name><name><surname>Lehtonen</surname><given-names>S</given-names></name><name><surname>de Boer</surname><given-names>CM</given-names></name><name><surname>Polo</surname><given-names>JM</given-names></name><name><surname>G&#x000f6;tz</surname><given-names>J</given-names></name><name><surname>Koistinaho</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>AR</given-names></name></person-group><article-title>Altered brain endothelial cell phenotype from a familial Alzheimer mutation and its potential implications for amyloid clearance and drug delivery</article-title><source>Stem Cell Rep</source><year>2020</year><volume>14</volume><fpage>924</fpage><lpage>939</lpage></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Oikari LE, Pandit R, Stewart R, Cun&#x000ed;-L&#x000f3;pez C, Quek H, Sutharsan R, Rantanen LM, Oksanen M, Lehtonen S, de Boer CM, Polo JM, G&#x000f6;tz J, Koistinaho J, White AR (2020) Altered brain endothelial cell phenotype from a familial Alzheimer mutation and its potential implications for amyloid clearance and drug delivery. Stem Cell Rep 14:924&#x02013;939</mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><mixed-citation publication-type="other">Vignone D, Gonzalez Paz O, Fini I, Cellucci A, Auciello G, Battista MR, Gloaguen I, Fortuni S, Cariulo C, Khetarpal V, Dominguez C, Mu&#x000f1;oz-Sanju&#x000e1;n I, Di Marco A (2022) Modelling the human blood-brain barrier in Huntington Disease. Int J Mol Sci 23</mixed-citation></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name><surname>Di Marco</surname><given-names>A</given-names></name><name><surname>Gonzalez Paz</surname><given-names>O</given-names></name><name><surname>Fini</surname><given-names>I</given-names></name><name><surname>Vignone</surname><given-names>D</given-names></name><name><surname>Cellucci</surname><given-names>A</given-names></name><name><surname>Battista</surname><given-names>MR</given-names></name><name><surname>Auciello</surname><given-names>G</given-names></name><name><surname>Orsatti</surname><given-names>L</given-names></name><name><surname>Zini</surname><given-names>M</given-names></name><name><surname>Monteagudo</surname><given-names>E</given-names></name><name><surname>Khetarpal</surname><given-names>V</given-names></name><name><surname>Rose</surname><given-names>M</given-names></name><name><surname>Dominguez</surname><given-names>C</given-names></name><name><surname>Herbst</surname><given-names>T</given-names></name><name><surname>Toledo-Sherman</surname><given-names>L</given-names></name><name><surname>Summa</surname><given-names>V</given-names></name></person-group><article-title>Application of an in Vitro Blood-Brain Barrier Model in the selection of experimental drug candidates for the treatment of Huntington&#x02019;s Disease</article-title><source>Mol Pharm</source><year>2019</year><volume>16</volume><fpage>2069</fpage><lpage>2082</lpage><pub-id pub-id-type="pmid">30916978</pub-id>
</element-citation><mixed-citation id="mc-CR112" publication-type="journal">Di Marco A, Gonzalez Paz O, Fini I, Vignone D, Cellucci A, Battista MR, Auciello G, Orsatti L, Zini M, Monteagudo E, Khetarpal V, Rose M, Dominguez C, Herbst T, Toledo-Sherman L, Summa V (2019) Application of an in Vitro Blood-Brain Barrier Model in the selection of experimental drug candidates for the treatment of Huntington&#x02019;s Disease. Mol Pharm 16:2069&#x02013;2082&#x00026; Mu&#x000f1;oz-Sanju&#x000e1;n I<pub-id pub-id-type="pmid">30916978</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><mixed-citation publication-type="other">Tashima T (2023) Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier. <italic>Antibodies (Basel)</italic> 12</mixed-citation></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name><surname>Linville</surname><given-names>RM</given-names></name><name><surname>Nerenberg</surname><given-names>RF</given-names></name><name><surname>Grifno</surname><given-names>G</given-names></name><name><surname>Arevalo</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Searson</surname><given-names>PC</given-names></name></person-group><article-title>Brain microvascular endothelial cell dysfunction in an isogenic juvenile iPSC model of Huntington&#x02019;s disease</article-title><source>Fluids Barriers CNS</source><year>2022</year><volume>19</volume><fpage>54</fpage><pub-id pub-id-type="pmid">35773691</pub-id>
</element-citation><mixed-citation id="mc-CR114" publication-type="journal">Linville RM, Nerenberg RF, Grifno G, Arevalo D, Guo Z, Searson PC (2022) Brain microvascular endothelial cell dysfunction in an isogenic juvenile iPSC model of Huntington&#x02019;s disease. Fluids Barriers CNS 19:54<pub-id pub-id-type="pmid">35773691</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>